1	Thursday, 3 May 2012
2	(9.45 am)
3	(Delay in proceedings)
4	(9.53 am)
5	PROFESSOR RUPERT RISDON (called)
6	Questions from MS ANYADIKE-DANES
7	THE CHAIRMAN: Good morning, professor. Thank you for
8	joining us. On the screen which we have, we have
9	a frozen picture of you, but your voice is coming over
10	fine. Can we move straight into the questioning, if
11	you are ready for that?
12	A. Yes, of course.
13	THE CHAIRMAN: Thank you very much.
14	You'll be questioned by Ms Anyadike-Danes.
15	MS ANYADIKE-DANES: Morning, professor.
16	A. Good morning.
17	Q. Professor, I wonder if you could first take us through
18	your qualifications and your experience.
19	A. I'm a consultant forensic paediatric pathologist. My
20	qualifications are, I'm a doctor of medicine, a fellow
21	of the Royal College of Pathologists and I hold the
22	diploma of medical jurisprudence.
23	How far back do you want me to go? I retired from
24	the NHS in 2004. Prior to that, I was professor and
25	head of department in histopathology at Great Ormond

1 Street Children's Hospital. I have a long experience of 2 both paediatric and adult pathology. I was consultant at Addenbrooke's Hospital in Cambridge before I went to 3 Great Ormond Street, and also at the London Hospital, 4 the Royal London, as it is now. 5 б I have been a consultant since 1972. 7 Thank you very much indeed. You were asked by the PSNI ο. 8 to produce a report for them, which I think you 9 produced. I'm not sure whether you can get the same 10 references as we do, but we have your report reference 093-031-081, and it's dated 2 June 2006. Do you have 11 that with you? 12 13 I looked at it last night. I can give you any details Α. 14 from it. 15 No, do you have a copy of it with you? Ο. I don't have -- I've got a copy of a number of things 16 Α. 17 here. I don't think I actually have that one. 18 I certainly have -- okay, I've got within the documents 19 that were given to me, there is a ... The substance of that report is written out for me. 20 21 Q. Right. The inquiry also asked you to deal with some 22 discrete issues, which you did, and you provided that 23 statement dealing with those issues, at least explaining 24 why you weren't able to deal with them, and that is dated 22 February 2011. We have its reference for the 25

1 record as 098/1. Do you have that with you?

2	Α.	I do have that with me, yes. I do have a transcript of
3		my first report, so I have that in front of me and
4		I have the answers to those questions.
5	Q.	Thank you very much. When the inquiry sought
6		a statement from you, can we just confirm the
7		documentation that you saw and also confirm the
8		documentation that was sent to you for the purpose of
9		you providing your report for the PSNI.
10		Just give me one moment. For the record, we have
11		a letter being sent to you on 16 May 2006 from
12		DS William Cross. The reference is 094-203-871. What
13		he says is he's providing the following for the purposes
14		of you giving them a report: four boxes of tissue
15		samples mounted in paraffin wax consisting of eight
16		samples from the lung, three from the liver, two from
17		the kidney, one from the spleen, one from the gland, one
18		the trachea, 15 from the brain and three from the spinal
19		cord and that they were all marked up in blocks. There
20		was also a letter sent to you from the renal
21		transplantation in Greater Glasgow and I will come to
22		that in a moment and another letter to you also from
23		UK Transplant. The post-mortem report of Dr Armour and
24		the report of Professor Berry and a statement from
25		Adam's mother consenting to the police assisting

1 well, you assisting them.

2		Now, that was the information provided to you before
3		you produced your report from the PSNI; is that right?
4	A.	I have no memory of that. And certainly, that
5		documentation, I wouldn't have kept this long after the
6		event. I have just the brief note that I have given in
7		my current statement. I can't remember exactly what
8		I was given at the time. The tissue samples and so on
9		were all returned. And you have to understand, I have
10		a very small office. I'm retired from practice now.
11		I never expected to hear any more of this, so they've
12		been shredded long since.
13	Q.	I understand that. But in any event, that's what the
14		letter seeking your advice says you received. But more
15		closer to today's date is the request that you received
16		from the inquiry.
17		Can I just confirm that the inquiry sent you certain

18 documents, which are attached as part of your witness statement that came back. They start at 098/1, page 12, 19 the first of which is a letter that UK Transplant sent 20 to the solicitor to the inquiry, addressing the issue of 21 the fate, if I can put it that way, of the other donor 22 kidney. The donor donated two kidneys, one which came 23 to Belfast and another which remained in Scotland. And 24 this letter deals with what happened to that kidney. 25

1 It's just to assist you in case you don't have it with 2 you.

It says:

3

"We follow up all our transplants at three months 4 past transplant and at that time we were notified that 5 б the transplant of the second kidney, which took place on 7 26 November 1995, had failed on the day of transplant 8 due to infection of the graft. At the time of reporting 9 this information to us, the hospital at which the 10 transplant was performed reported that the recipient was alive." 11

12 Now, we went back again and this letter was also in 13 your papers, it's a letter from NHS Transplant, again to the solicitor to the inquiry dated 3 June. That's 14 15 098/1, page 13. That letter deals with a number of queries in relation both to what happened to the kidney 16 17 that went to Adam, before it was sent to Belfast but, for present purposes, gave more information about the 18 fate of the kidney that remained in Scotland, and one 19 20 finds that on page 14.

21 It says:

22 "The other kidney was transplanted on 26 November 23 but failed due to poor recipient arteries, which were 24 very thin and attenuated and infection of graft was 25 recorded as the cause of death but there was no

1 evidence ..."

2 (Alarm sounds) (Pause). 3 "There was no evidence of infection within the graft 4 although he did have post-operative pyrexia. Subsequent 5 б scans show that the kidney was not adequately perfused 7 and the kidney was removed after about a week. The 8 donor was still alive at the three-month follow-up. 9 There was no record of infection recorded for either 10 kidney when they were removed from the donor at Glasgow Southern General Hospital." 11 12 Then, of course, you were supplied with the kidney 13 donor information form. So I don't know if you remember seeing that --14 15 sorry? I have got copies of those here. 16 Α. 17 Q. Thank you. So you provided your report and it's to 18 those two reports that I want to focus on. If I can tell you the scheme of what I have in mind. 19 20 I would like, first, if you could explain your 21 methodology, how you went about compiling your report, 22 help us with how you interpreted the results that you 23 received, and then your view, if you can give it, on the 24 cause of infarction, and certainly your confirmation as to why you think the time, albeit a judgment, is as 25

б

1 you have given it.

2	Once we have that, then I would like you to consider
3	the views of those who were actually present in the
4	operating theatre and have described variously the
5	colour of the donor kidney, its perfusion, pulsatile
б	flow and production of urine. Not all of them agree
7	with each other, but those are the issues that they deal
8	with, if I can put it that way.

9 Then I would like you to help us with how your view 10 is -- well, your observations, if I can put it that way, 11 on the report on autopsy, and then your observations on 12 the findings of Professor Berry, who was asked to 13 perform a similar exercise as you were, but that time instructed by the coroner. I will take you to his 14 15 reports and ask you for your observations and comments 16 on them.

17 I would like, then, to move on to the comments of other experts who have considered the kidney and what 18 they feel or their view as to its condition when it was 19 20 transplanted and what some of the reasons might be for what happened to it. That is principally 21 22 Professor Koffman, who is a consultant transplant 23 surgeon, and Messrs Forsythe and Rigg, who are the 24 expert transplant surgeons for the inquiry. And then 25 finally the view of Dr Coulthard, who is the expert

nephrologist for the inquiry. And then once we have
 gone through that, I will ask you for, in the light of
 all of that, your concluded view.

Obviously, if at any stage you feel that I've asked 4 you something that you really can't comment on, it's 5 б outside your area, then obviously you say that. But 7 these are the issues that are of concern, not just to 8 the inquiry but also the interested parties. And if you 9 could help us with them, we would be grateful. 10 THE CHAIRMAN: Sorry, can we just pause for a moment? There's an interference with sound, which I think ... 11 12 Professor, could you allow us two minutes? There's some 13 interference on our end with sound, which is causing 14 some problems. Do you want to break the link and call 15 back? We'll call you back in a moment or two. I shan't move. I shall be here. 16 Δ 17 MS ANYADIKE-DANES: Thank you very much indeed. 18 (Pause). THE CHAIRMAN: Professor, can you hear us again? (Pause). 19 20 I can't hear you, I'm afraid. 21 Can you hear us now, professor? I'm sorry, if you 22 wait for one moment because we can't hear you. 23 (Pause). 24 Professor, can you hear us now? It doesn't sound like it. 25 (Pause).

2 (10.09 am) (A short break) 3 4 (10.19 am)5 THE CHAIRMAN: Are we back? б A. Yes. 7 THE CHAIRMAN: Professor, thank you for your patience. 8 A. That's okay. 9 MS ANYADIKE-DANES: Thank you. Professor, despite the 10 interference, I hope you were able to hear the rough plan of the questioning I had? 11

We'll take five minutes.

1

12 A. Yes, yes, I did hear that.

Q. Thank you very much indeed. I wonder if we could just start with what I've called your methodology, how you actually went about the exercise of examining these samples.

A. I looked at them down a microscope. I'm not quite sure
what you mean by methodology. I am a histopathologist.
I examine histological slides down a microscope, I form
an opinion about them and I write a report. I mean,
there isn't any other methodology than that.

22 Q. Can you explain what you're looking for?

A. No, that would be to describe the whole profession of
histopathology. One looks at a slide and looks for
various forms of pathology. Now, in this particular

slide, this particular set, the pathology was -significant pathology was confined to the sections of
the child's own kidney, which confirmed the clinical
diagnosis of cystic dysplasia with quite severe kidney
damage in the original kidney. In the sections from the
transplant, the transplant was completely infarcted, it
was just dead.

8 Q. I understand.

9 A. Okay? Now --

10 Sorry, what I was going to ask you is, were you able to Ο. know whether the samples that you were looking at from 11 12 the transplanted kidney came from a particular section 13 of the kidney or whether they came from a number of 14 different places in that kidney? One's trying to see 15 how representative what you were looking at might be. The person doing the post-mortem would form an opinion 16 Α. 17 as to whether the change was diffuse, involving the 18 whole organ, or there were different areas. Had that 19 been so, they would have taken different areas. As 20 I remember, I think there were two areas but they showed 21 completely the same changes. So the implication of 22 that is that the whole kidney is affected in the same 23 way.

Q. Thank you very much. If you'd had any cause to beconcerned about whether you were looking at something

1 that was localised or generalised, would it be your
2 practice to communicate back and say, "Can I see some
3 other samples?"

4 A. I was satisfied that these were representative of the5 kidney as a whole.

6 Q. Thank you.

7 Α. There are two things that I would like to ask you before 8 we go any further. In all the papers, one of the things 9 is that there is some discrepancy between my 10 understanding of how long the child survived after the transplantation and what I read from Professor Berry's 11 12 reports. Now, my understanding was that the child died 13 within 24 hours of the transplant. His suggestion that it may be a longer period. That's important in terms of 14 15 my interpretation of the changes.

So it would be useful if you could tell me two 16 17 things. One, how long after the operation the child 18 survived. And, two, I know it's the practice in Ireland 19 to perform post-mortems very soon after death, I would 20 like to know whether the child's body -- whether there 21 was a significant period of time between the child dying 22 and having a post-mortem examination, because both of those things would have some bearing on the changes that 23 24 I see down the microscope.

25 Q. I understand. Ventilatory support was withdrawn from

1 Adam at 11.30 on 28 November 1995.

2	A.	And it was the the operation occurred on the 27th; is
3		that correct?
4	Q.	Yes. The operation was concluded somewhere in and about
5		noon on 27 November.
б	Α.	It's about 24 hours later?
7	Q.	It's about 24 hours later. I can tell you the times
8		when the brainstem
9	Α.	It doesn't matter absolutely precisely. That was my
10		understanding, that it was about 24 hours. And can
11		I confirm that there was not a long delay between the
12		child dying and the post-mortem examination?
13	Q.	No, there wasn't. The post-mortem itself was conducted
14		at 2.40 on 29 November. So ventilatory support is
15		withdrawn at 11.30-odd on the 28th; the post-mortem
16		takes place at 2.40 on the 29th.
17	A.	Thank you very much for that. Okay. You should be
18		asking me the questions.
19	Q.	No, I want to give you whatever information is necessary
20		that you can assist us with your view. What we are
21		trying to understand is how you reached the view you do
22		about the timing.
23	A.	Okay. Well, it's really a matter of experience. In the
24		tissue in which the blood supply has been completely
25		removed, the tissue will die and changes will be

recognisable that it has died over a period of time
 after that. If I can give you a more familiar example.
 Q. Yes.

If somebody suffers a heart attack -- okay? -- they 4 Α. clutch their chest with pain because a coronary artery 5 б has been blocked by a thrombus. Okay? Now, they might 7 die almost immediately, and if their heart was examined 8 at that stage, it would look completely normal, even 9 though the blood supply had been completely withdrawn. It takes about 12 hours for anything to be recognisable 10 histologically and about 24 hours before there is clear 11 12 evidence that the heart tissue has suffered a loss of 13 blood supply.

So the point I'm making is that we're talking about 14 15 a 24-hour period between the transplant being put in and the tissue being examined, albeit a day later, at 16 17 post-mortem. And the complete degree of infarction with virtually no sign of the individual structure of the 18 19 tissue, other than in ghost form, after 24 hours would be quite remarkable, in my view. I would expect that to 20 21 take at least two days.

Q. If I may ask you something about timing. I wonder if you could help us with two scenarios. Let's take the one when either just before or for some reason at the time of literal transplant the kidney suffers a loss of

blood supply and oxygen and so forth. Let's say 1 2 that is, therefore, happening, I don't know, noon or whatever -- I don't know how precise these things have 3 4 to be -- on the 27th. So that has happened. The kidney is not having an adequate blood supply and that 5 б continues on, and then the ventilatory support is 7 withdrawn at roughly 24 hours in the morning of the next 8 day, and then you do your autopsy the day after that.

9 So if there's that situation where that kidney could 10 have been effectively without a blood supply for not just the period from when the ventilatory support was 11 12 withdrawn but almost from the moment of the surgery, and 13 then if we can contrast that with a situation where 14 there was absolutely nothing wrong with the kidney when 15 it was transplanted but the ventilatory support is withdrawn and then you are asked to, amongst a range of 16 17 other slides, look at the slides of the transplant kidney. So in that case, you're dealing with a loss of 18 19 supply from whenever the ventilatory support is withdrawn until the autopsy is carried out, you see 20 21 those results when you're looking at it. Do you see what I mean by those two scenarios? Can you help us 22 with the difference of what you would expect to see? 23 24 I'm not quite sure I get it completely. You're saying Α. 25 that --

1 Q. It's a longer period. If the kidney --

2	Α.	Okay, the transplant is performed. The child is on
3		respiratory support almost immediately after that for
4		another 24 hours, then the support is withdrawn.
5	Q.	Yes.
б	A.	And is the child certified dead at that point?
7	Q.	Yes. If you've got that scenario
8	A.	So there is 24 hours between the kidney being
9		implanted and the child's death.
10	Q.	Healthy kidney being implanted and then the child dying.
11		Yes, that was the second scenario I put to you. The
12		first
13	A.	The first scenario
14	Q.	It's a difficulty for the stenographer if we talk over
15		each other. That was a second scenario that I put to
16		you, which is a perfectly healthy kidney at transplant
17		goes in and the child suffers the cerebral oedema and
18		dies and ventilatory support is withdrawn. So it's
19		going in at about noon, or thereabouts, on 27 November.
20		Ventilatory support is withdrawn the follow day.
21		There's that scenario. Okay?
22		The first scenario I had to put to you is when the
23		supply to the kidney is compromised, either there's
24		a problem with the kidney just before it goes in or as
25		part of the process of it going in, it's compromised, so

it has an inadequate blood supply right from the outset.
 A. Yes.

Q. So there is a longer period, if I can put it that way, where it is not receiving a blood supply, and I was putting that to you. So what I'm trying to see is your view about those two different timings, if I can put it that way.

I think you raised another very important point, and 8 Α. 9 that is to seek to get that degree of precision out of a subjective interpretation of a kidney [loss of sound] 10 microscope is just impossible. You cannot time events 11 with that degree of precision. I know it would be nice 12 13 from a lawyer's point of view if you could, but you 14 cannot. The scenario you just described adds on two or 15 three hours or something like that to the other time 16 frame.

17 Q. I think it may add more than that. Let's just be clear 18 about the timings that I'm putting to you so that we're 19 clear on it.

20 The transplant is finished at noon, let us say, on
21 27 November. That's one important time.

Ventilatory support is withdrawn at, I think it's,
11.30, the following day, the 28th. That's another
scenario.

25 And, then, thereon it's a matter of when the slides

then are taken at, I think it was, 2.40, on the 29th. 1 2 So that's what you're looking at. A. Yes. Between the child's death and the tissue being 3 4 removed post-mortem is less important. I only asked that because if it's a considerable period of time that 5 б in itself might cause deterioration in the 7 appearances --I understand? 8 Q. 9 Α. The time interval that you're talking that won't 10 add another dimension to the equation. And neither would a couple of hours either way because, as I say, 11 12 this isn't a precise science. 13 However, if one was talking, you know, not in 14 a transplant situation, maybe -- what shall we say? --15 in the course of an operation, a surgeon had inadvertently tied the blood vessel to a perfectly 16 17 normal kidney, you wouldn't expect the sort of changes

18 that I saw down the microscope here to occur in that 19 sort of period of time. It would be really pushing it 20 for that to happen.

21 Now, I think there's another point that is important 22 here, and that is the transplant kidney doesn't go 23 straight from the donor into the recipient. There is 24 a period of time when it is perfused, kept on ice, 25 et cetera. And I understand from the other documents

that a degree of renal tubular necrosis, particularly if 1 2 it's a very long period, as I believe it was about 30 plus hours in this child's case. That in itself might 3 produce changes in the renal tubules that I would 4 recognise at post-mortem. So it isn't quite the same as 5 a perfectly normal kidney going into a child and then 6 7 24 hours later -- so I think you'd have to factor that in to what one is seeing. 8

9 But I think at one point Professor Berry suggests that the event that caused the non-perfusion of this 10 kidney must have occurred either at the time of 11 12 transplantation or thereabouts. Now, I would agree with 13 that. That would be the shortest period of time that 14 you could envisage, even taking into account that the 15 kidney was not a normal kidney, in the normal sense of the term, it was a kidney that had already been stored 16 17 for 30 hours and perfused.

18 I think that you would certainly -- I don't think 19 there would be any period of time after transplant surgery had been completed when that kidney would have 20 21 functioned. That would be my view from the histology. And that is taking account, as I say, that this is not 22 23 an exact science, but the degree of change, in my view, 24 would have taken at least that period of time to occur. So I don't -- one scenario that I would like to get rid 25

of, and that's the only contribution I think I can make here, is that that kidney wasn't perfectly normal for some hours after transplant and then something happened at that time. Whatever happened, it happened during the procedure that that child received the kidney.

Now, the other thing I would say about timing with 6 7 regard to histological changes here is that because it's 8 so imprecise, one is very open when one is asked by 9 a lawyer how long does this take, how long does that take. You take very careful cognisance of what other 10 people who might have been there when whatever it was 11 12 happened, what they think. Now, it seems to me that 13 when the kidney was first put in, many people thought 14 that at that time it was being perfused, although 15 there's some difference of opinion as to whether it was 16 still doing so at the end of the operation.

17 Now, my only contribution would be that I think 18 something did happen at that time or immediately after 19 the procedure was finished, and there would be no way that the changes that I and Professor Berry saw in the 20 21 kidneys from the autopsy could have developed in a shorter time than that. Do you see what I mean? 22 23 Q. Yes. 24 Α. So something must have happened at the time, roughly

25

19

at the time of the procedure occurred. Because they

were so advanced, my first thought was that it actually wasn't viable before it was put in, but I've taken note of what other contributors, particularly the clinicians, have said. And also another reason why I said that was the fact that I had been told that the other donor kidney of the pair that went to Glasgow had also failed.

7 Now, it's quite clear that that failed for a completely different reason, so I don't think one can 8 9 use that as evidence that both kidneys in some way were irretrievably compromised before they went in. I think 10 they're two different scenarios. And I take the point 11 that -- the observations that were made at the time of 12 13 the surgery, but I would still stick to the point that 14 something happened to that kidney at least at that time 15 or immediately afterwards, and there has been no period after the operation where that kidney worked normally 16 17 and then something else happened.

Is that too complicated?

18

19 Q. No, it's not. You have just brought me to the very 20 point. Just for people who are following it, if I can 21 benchmark a few things for them from what you were 22 saying in terms of Professor Berry. His point was at 23 011-007-022.

What he said was very straightforwardly:"The transplant kidney was infarcted, dead. The

extent of change suggested that this occurred at or 1 2 before the time of transplantation." 3 I think that's a point you were making. And then he went on in his -- he had a sort of letter back to the 4 Coroner when he said -- this is the letter of 25 March, 5 б 011-053-187: 7 "My only contribution is that I doubt this kidney would ever have functioned." 8 9 Then to bring him up to the statement he made for the PSNI, and this introduced, I think, some of the 10 sorts of qualifications that you've referred to. That's 11 at 093-030-079. 12 13 He said: "The microscopic changes were sufficiently 14 15 well-established that I estimated that the damage had occurred about two days previously before or around the 16 17 time of transplantation." He says, as you do, that the estimate of timing is 18 19 not exact. Then he says: "Could be overridden by strong clinical evidence 20 21 that the kidney was functioning normally after that 22 time." 23 "After that time", presumably meaning after 24 transplantation. Then he says: 25

"This view would be strengthened if the other donor 1 2 kidney failed to function was found to be infarcted." 3 And finally: "A single sample of a whole kidney does not 4 necessarily prove that the whole kidney was infarcted." 5 б Finally: 7 "I do not know what the kidney looked like to the 8 naked eye inspection." 9 I think those are the points that you were bringing out in your explanation to us. 10 You have looked at the views -- or the descriptions, 11 12 I should say, of the kidney from the other clinicians 13 and you know they're not all entirely consistent, but 14 you say that you factored them in, and even having done 15 that, you are still of the view that this is a kidney which the process that you have described may have 16 17 started slightly beforehand because of the long ischaemic period, but certainly was starting at or 18 around the time of transplantation. Would that be 19 a fair way of summarising it? 20 21 Α. That would be exactly it. I think that very much agrees 22 with what you quoted from Professor Berry. I think his 23 point, you know, at or very close to the time the kidney 24 was inserted would be entirely my own view as well, accepting that it is difficult. 25

I think one has to take some cognisance of the fact that more than one of the people at the operation felt that the kidney at least initially perfused. So I think one would have to that take. But there is some difference of opinion as to whether the kidney appeared normal throughout the procedure.

7 And my point would be, I don't think -- in the same way as Professor Berry is saying, I don't think this 8 9 kidney would have ever have functioned normally after the transplant. I would entirely agree with that based 10 on the extent or the advanced state of infarction in the 11 kidney. As Professor Berry said, this kidney was dead. 12 I wonder if you can help us with this, and I may be 13 Q. 14 showing my ignorance of your science. Is there any way 15 of being able to distinguish between the damage that's done through the long ischaemic time period and the 16 17 damage that's done, if that's what it is, through depriving the kidney of an adequate blood supply? 18 19 Α. Yes.

Q. Either the type of damage or the place where you wouldsee that damage.

A. Yes. I think the point is that the most sensitive cells
in the kidney to a loss of perfusion are those that line
the kidney tubules. The urine -- there are little
structures called glomeruli, which are perfused by

blood, and it's clearly from the blood that forms the urine, which then passes down the tubule. Okay?

Now, if there is significant loss of perfusion, the first change you would see under the microscope would be in the tubules. So you could have a stage where the tubular cells are clearly in the process of being destroyed, whereas the glomerulus might look relatively normal. That's why the term "renal tubular necrosis" is used, because the tubules are affected first.

Now, it could well be, and I picked this up from 10 some of the other experts' comments, that sometimes when 11 a kidney has a fairly long ischaemic time before it's 12 13 inserted that the patient may fail to produce urine 14 because their renal tubules are necrotic, and it may 15 take several days or even longer before those cells regenerate and the kidney works again. So it implies 16 17 that there has been significant damage to the tubules at 18 least during the time that the kidney is ischaemic, even in those kidneys that worked perfectly normally 19 afterwards. 20

21 What I'm saying here is that one would have to take 22 cognisance of the fact that some of the changes or maybe 23 all of the changes that you see in the tubule may be due 24 to a prolonged ischaemic time and they've never 25 recovered because the perfusion has never been effective

after the kidney's been put in, and during that time 1 2 changes also occur in the glomeruli. I mean, that would be a perfectly feasible scenario that the tubules are 3 already badly damaged and following or during or 4 following the operation, poor perfusion has the same 5 б effect on the glomeruli as it does on the tubules. 7 Q. If I might interject there and help you, I think the 8 person who discusses that in a report is 9 Professor Koffman, and he discusses that in a report that he provided to the PSNI. The reference for that is 10 094-007-039. It's at paragraph 4.8. 11 12 He says: 13 "The fact that the kidney appeared to change colour 14 and become less well perfused during the operation again 15 is a phenomenon which occurs not infrequently and 16 usually denotes acute tubular necrosis, which is 17 a recoverable process usually caused by a prolonged 18 storage time." 19 So that seems to equate with what you're saying, that unfortunately, though, it didn't get to the stage 20 21 where it could recover --Precisely. 22 Α. 23 Q. -- if I understand what you're saying? 24 Α. It was from that opinion that I made the suggestion that I've just done now. I think that's perfectly plausible. 25

But I don't think that you would have got the changes in the glomeruli, and something happened very --J Q. I'm going to ask you about that. If we can then go on in his report, and you may help us with this, he then says at 094-007-040 at paragraph 4.10:

6 "It is likely that the kidney infarcted soon after 7 the operation was complete and there would probably have 8 been either thrombosis in the renal artery or vein."

9 He goes on to express the view that he thought the
10 kidney was viable when it was transplanted. But that's
11 not the bit that I'm asking you to comment on.

12 I wonder if you saw any evidence of this, that there 13 would probably have been either thrombosis in the renal 14 artery or vein. Is that something you could see any 15 evidence of?

It would be something that you would be -- more usefully 16 Α. 17 look for at post-mortem, because we just have a section 18 of the kidney. You would need to follow the artery or 19 the vein up to see whether there's any thrombus in it. Q. I understand that. A post-mortem, it's a very, very 20 21 cryptic description of matters, but what we do have is -- it's 011-010-038. It says under "Transplanted 22 23 kidney":

24 "Was in situ in the right pelvis. The ureter25 drained freely and the vascular attachments were

1 intact."

2 And then the other comment that she has to say is at 011-010-040 under "Transplanted kidney": 3 "There was complete infarction." 4 5 Now, does that help you as to whether the б pathologist was attempting to describe whether there was 7 thrombosis in the renal artery and vein or not? I think what she would be looking for would be -- she 8 Α. 9 would be looking at the anastomosis, where the surgeon 10 had sutured the vessels together to make sure that they were intact and there hadn't been any technical problem 11 12 at that stage. I don't think she would -- I think if she would be specifically looking for thrombi it would 13 14 have said so in the report. 15 I understand that. I wonder if you can help us with Ο. this. So you have identified the tubular necrosis that 16 17 Professor Koffman has talked about, and you have said that that could be attributed to its long ischaemic 18 19 time. But you say that's not all that you saw and it's not for that that you've come to the conclusion that the 20 21 kidney was infarcted at or round about the time of 22 transplant. You went on to say other damage that you 23 had seen which wasn't compatible with simply a kidney 24 that had been overlong in storage, if I can put it that way. So can you help to describe what else you saw that 25

1

has led you to this conclusion?

2 I don't think there is -- I think what I have described Α. is why I've come to the conclusion that I have. I mean, 3 I hadn't actually considered the possibility that under 4 normal circumstances with a transplant that has had 5 a long ischaemic time, some damage to the tubules is 6 7 actually quite common. I didn't know that. But 8 clearly, from the experts' letter, this is so. So at 9 least some of the changes that I see could be related to that rather than just to lack of blood supply. 10

I mean, I was looking at it from the point of view 11 12 of how long would it take a perfectly normal tissue to go from perfectly normal to the degree of ischaemic 13 14 necrosis that I saw in the sections. I think you would 15 have to modify that a bit to say that the fact that the 16 tubules might have been damaged earlier than that would 17 have some effect on the appearances and, therefore, 18 I think the observations that the kidney appeared to 19 perfuse when it was first put in are probably relevant. 20 But at the same time, I would take the point, which 21 Professor Berry also makes, that I don't think this kidney would ever -- after the operation was complete, 22 23 would ever have had any meaningful function. 24 Yes. I understand that. But there are issues that Q. depend upon or at least relate to whether you're saying 25

that notwithstanding the fact that some of the damage 1 2 that you detected could have been there prior to transplant and therefore, I suppose in layman's terms, 3 4 shouldn't be used to extend the time that you think the kidney was infarcted for, if I can put it that way. But 5 б it is nonetheless important if you help us with, even if 7 you leave that aside, the other damage that you detected 8 to the glomeruli was such that you are pretty firm in 9 your view as to what the implications of that extent of damage is or are, rather. 10

11 A. Yes. I would agree with that.

12 So because of that damage, are you, therefore, of the Q. 13 view that this kidney really must have been compromised 14 at roughly the time that you and Professor Berry put it, 15 which is round about the time of the transplant? Irrespective of whatever other damage it may have 16 17 sustained as a result of the ischaemic time? 18 Α. Yes.

19 Q. In a way, we've sort of entered into the territory, and 20 you were doing it, I think, when you gave us the example 21 of the person who sustained a heart attack. But 22 I wonder if you could help us a little more with how 23 that damage is actually caused. What is the cause of 24 the damage that you saw, so far as you can help us with 25 that?

A. If you withdraw blood supply to an organ or even part of
an organ, the tissue -- if you obstruct or cut the blood
supply, then the area of tissue that is supplied by that
vessel will die. This is what we mean by an infarct.
An infarct means death of a tissue as a result of
withdrawing its blood supply.

Now, what happens, in terms of what you see under the microscope, is that over a period of 12 to 24 to 36 hours the cells in that tissue will lose their normal characteristics, their nuclei will become small and condensed, the [loss of sound] cells will change. All those things are things that we recognise down the microscope.

14 But going back to my analogy with the [loss of 15 sound] you can completely compromise the blood supply to an area of tissue, but it will be at least 12 hours or 16 17 more before you would actually be able to recognise 18 changes down the microscope. So the fact that I can see 19 changes in the glomeruli and in the blood vessels here means that it's longer than that. Do you see what 20 21 I mean?

22 Q. I do.

A. So we're talking about up to 24 hours even in that
scenario, and this is the sort of length of time we're
talking about. That's why I bring is back to something

happening at or very, very soon after the surgery. 1 2 And it may be that this is outside your area, but are Ο. you able to express a view of the kind of thing that 3 would happen to produce that result? 4 No. That's a clinical question. You have loads of 5 Α. б clinicians here who are much better qualified. 7 ο. I was going to go through with you the views of the 8 clinicians in the sense of -- although we know that 9 they're not all consistent, but one way or another they 10 all speak about the colour at various times of the kidney, its perfusion, whether or not it produced urine, 11 12 although I think it's only the surgeon who considers it 13 does. None of these things are very clear, as you 14 probably have detected from their witness statements and 15 their notes. But, nonetheless, they all raise them, if 16 I can put it that way.

17 I was going to go through those with you, and I was also going to go through Professor Berry's views with 18 you and Professor Koffman. But it seems one way or 19 20 another you have actually covered those by having 21 accepted that you have read those and taken them into 22 consideration in your view. So unless somebody else specifically wants me to take you to something, I don't 23 24 particularly feel it's necessary to take you to all of 25 those.

But I would just ask you now, in the round, having read all of that and reflected on it, can you give us your final view of the timing of infarction of this kidney?

Yes. Could I just say that, as far as the observations 5 Α. б of kidney colour made by the clinicians, that's right 7 outside my area of expertise so I wouldn't want to go down that -- but as far as Professor Berry's comments 8 9 are concerned, I would really go along with him. I mean, I think we're in more or less complete agreement 10 that this is an infarcted kidney that suffered a loss of 11 12 perfusion at or very close to the time that the 13 transplant was inserted. And I think there is good 14 reason for suggesting that.

I think my first suggestion that something might have occurred before the kidney was transplanted, I think that's really sorted out by Mr Koffman's letter, where he's saying that some degree of tubular damage is quite common in kidneys that have a long ischaemic time before they're inserted.

I wasn't aware of that. Had I been aware of that, I would have tailored my opinion to that to say that particularly with all the clinical evidence, that I think something happened to that kidney at round about the time that it was inserted, maybe at the end of the

procedure rather than the beginning, but I don't think
that kidney could ever have had any meaningful function
after that.

4 Q. Just to be clear --

5 THE CHAIRMAN: Professor, can I interrupt for one moment б just so I understand it clearly. You agreed a few 7 minutes ago with Professor Berry's report in which he 8 said that his view was that the damage occurred about 9 two days previously at round about the time of 10 transplant, and he would hold that view unless there was strong clinical evidence that the kidney was functioning 11 normally at that time. Right? 12

13 A. Yes.

14 THE CHAIRMAN: I have to take a view about how strong that 15 clinical evidence is, but if that clinical evidence was 16 strong that the kidney was functioning at the time of 17 the transplant, what is the alternative explanation of 18 when the damage occurred? Or is there an alternative 19 explanation?

A. That's actually quite a complicated question, and some of the reasons that I've been going through -- I mean, I think the danger is taking the kidney when it first goes in as being a perfectly normal organ. Okay? And what the clinicians are talking about is whether it is being perfused with blood, which would be things

like: can you see the vessel pulsating? Has the kidney
 become pink? This sort of thing. As far as I can tell,
 that did happen when the kidney was immediately put in.

But in terms of what we see 24 hours later, we have to take cognisance of the fact that there may have been some damage to the kidney tubules before all that happened. That damage might have been something that under normal circumstances could have regenerated and been got over. In this particular case it didn't.

Again, the issue over how long this happened --10 I mean, Professor Berry was obviously under the 11 12 impression that there was two days between the operation 13 and death, which is why I queried it in the first place. But at the same time, I think the clinical evidence and 14 15 the fact that people actually saw the [loss of sound] 16 pulsate, the kidney appeared to become pink, I think 17 some blood must have perfused through the kidney at that 18 point.

What I'm unclear about is what stage after that the perfusion became sub-optimal or even stopped, and whether it was during -- I mean, after all, the operation isn't a single moment in time, it's a four-hour procedure. Whether during that period something happened or immediately after the procedure was finished. My view is that in terms of an operation

being complete and now you go away with a kidney that is functioning, I don't think so. I don't think that kidney ever had any meaningful function by the time the whole transplantation procedure was complete.

5 THE CHAIRMAN: Thank you.

6 A. After it was complete.

7 MS ANYADIKE-DANES: Thank you. Just to clarify one point. 8 When you produced your first report, you said you had 9 not taken into consideration the damage that you were seeing could include damage that the kidney had already 10 sustained through its long ischaemic time. So you took 11 12 all the damage together and took a view in your 13 professional judgment as to what that meant in terms of 14 when that kidney ceased to have an adequate blood 15 supply. And the question that I wanted to raise with you is, now that you know that some of that damage might 16 17 actually have happened before transplant and so the damage that could have resulted from the -- let's 18 call -- it the inadequate blood supply, it's a slightly 19 different damage than you had originally thought. Does 20 21 that affect at all your view of when you thought the kidney or think the kidney infarcted? 22

A. I think when I talk about damage occurring at the time
of transplantation or maybe before, I think some of the
damage did occur before and it was the result of the

long ischaemic time. Now, I wasn't aware of that when I wrote the report. But in actual fact my report is probably still correct. There was some damage before the kidney was actually transplanted and more damaged subsequently. But it would have an effect on what that kidney looked like under the microscope 24 hours after the transplantation.

8 I mean, I'm quite happy to accept that some of the 9 changes that I saw in the tubules might well have been 10 due to the long ischaemic time, which under normal circumstances wouldn't have mattered. The kidney would 11 12 eventually -- what happens is that those necrotic cells 13 in the tubules regrow as normal cells and then the 14 kidney functions. That is what apparently normally 15 happens but didn't have the opportunity to do so in this 16 case.

Q. So now that you recognise about the long ischaemic time and how you can attribute some of the damage you saw to that cause, I think what you're saying, it's what I want confirmation on, is that doesn't affect when you think that kidney was likely to have infarcted?

22 A. Yes, that's correct.

23 Q. Thank you. That's the point I wanted clarifying.

24 Mr Chairman, I don't think I have any further 25 questions.
THE CHAIRMAN: Professor, could you wait one moment while 1 2 I just check if there are any questions? MR MILLAR: If we could just ask the professor to wait for 3 a couple of moments if that would be convenient. 4 THE CHAIRMAN: Yes. Professor, just allow us a few moments, 5 б please. (Pause). 7 MS ANYADIKE-DANES: Thank you, professor, for waiting. 8 There is one further issue to raise. As you have been 9 talking about the kidney being deprived -- or the donor kidney being deprived of its blood supply and, 10 therefore, oxygen and the effects of that which you have 11 described, an issue arises as to what the general effect 12 13 of the patient, the recipient, being deprived of 14 adequate oxygen is. As you will know from the 15 post-mortem report, the results of the autopsy were, and indeed the verdict on inquest, that Adam died as 16 17 a result of acute cerebral oedema. The result of that 18 oedema was that he coned, herniated and therefore died. 19 The issue is this. If that was happening and there is a live issue as to when it happened, it is believed 20 21 by some of the experts that it could have happened anywhere between 8.30, 9, 9.30, maybe just before noon, 22 23 but there is a range of hours in which that could have 24 happened. The question for you is, if that happened in that 25

way, is that likely to have had any effect on what you 1 2 would see as the damage to the kidney? And, therefore, I suppose, the question is, could the damage to the 3 kidney have started, leaving aside the tubular necrosis 4 point, in advance of what you have described as 5 б something happening in and around the transplant? 7 Α. That's almost how long is a piece of string? I'm quite 8 happy to accept that other particularly extreme 9 processes going on in Adam's body might well have 10 affected the perfusion of the kidney, but it would mean that -- it would be something that would be happening 11 12 almost immediately after the transplant occurred, and it 13 could well be that whatever caused the cerebral oedema 14 could have also caused compromise of the perfusion of 15 the kidney.

The actual cerebral oedema is a very dangerous 16 17 thing, as we've seen here, it can cause death, but it 18 has a myriad of causes. There could be a number of reasons why that happened. And I don't think it is for 19 me as a pathologist to really go into that. These are 20 21 clinical issues from the people who were looking after 22 him in intensive care, but I'm quite happy to accept the 23 possibility that whatever those processes were, they 24 might also have affected the perfusion of the kidney. Yes, I think the point is that if it could have that 25 Ο.

effect -- and we're not asking you to address the 1 2 question of whether he did or did not develop cerebral oedema, and if he did, how he did. But assuming that 3 4 that is what was happening and that he was coning at some point prior to the completion of his surgery, 5 б assume that, and if you accept that that process could 7 have had an effect on the oxygen to the transplanted 8 kidney, along with everywhere else in his body, 9 I presume, does that change your view as to when the 10 kidney might have infarcted? Does it have any effect on the conclusion that you've given us today? 11 12 Not in terms of timing because what is going on in the Α. 13 kidney in terms of what I see down the microscope is 14 independent of what might be happening elsewhere. What 15 I'm saying is that the process that caused the poor perfusion or even absent perfusion of blood through the 16 17 kidney might well have something to do with the other 18 processes that were going on in this child at the same Is that ... I don't know whether I've really 19 time. answered your question or not. 20 21 Well, I think you have answered it partially. I suppose Ο.

the question really is -- I think you've described it as a combination of effects. You're looking at the end stage, you can see how the kidney looks at the end stage, and you're working back from that to say: if I'm

seeing this level of damage, how long do I think it's 1 2 likely to have taken for that level of damage to be produced? Is that not effectively what you're saying? 3 4 That's exactly so. But this child was very ill with Α. 5 a number of processes going on, and it's very, very б difficult to dissect one from the other. But in terms 7 of the kidney alone, which is what I'm focused on, for 8 the appearances that I saw from the post-mortem kidney, 9 I'm talking about a sort of minimum time that the 10 clinical observations would suggest was appropriate; in other words, the kidney did function, albeit briefly 11 perhaps, but certainly after the procedure was finished 12 13 I don't think there was any significant renal function 14 from that kidney, for whatever reason, whether it is 15 related to the other things that were going on in the child's body at the same time. But I'm looking at it 16 17 just from the point of view of the kidney. 18 MS ANYADIKE-DANES: Thank you very much indeed, professor. 19 THE CHAIRMAN: Thank you very much. Professor, we're going 20 to cut the link now. Thank you very much for your time. 21 Thank you very much indeed. Α. 22 THE CHAIRMAN: Ladies and gentlemen, we'll take a break now 23 for 15 minutes and we'll resume with Dr Haynes. Thank 24 you.

25 (11.08 am)

1 (A short break) 2 (11.30 am) DR SIMON ROBERT HAYNES (continued) 3 Questions from MS ANYADIKE-DANES (continued) 4 MS ANYADIKE-DANES: Good morning, Dr Haynes. I had 5 б indicated that we would be going on to look at the issue 7 of atracurium and the matters that follow on in terms of 8 brainstem death and so on. But I've been asked before 9 I deal with that if there are two things that I would address, which really go to the question of blood loss. 10 The first, if I may take you to the blood swab or 11 12 the blood loss count and ask for your views on this. 13 Let me pull it up. It's 058-007-021. 14 You have seen that before, haven't you? 15 Yes. Α. So that's the count. It's registered by the nurses. 16 Q. 17 One of the nurses, Staff Nurse Mathewson, gave evidence on 30 April, this month, about that count in order to 18 try and assist in what the actual extent of blood loss 19 was likely to have been. Nobody knows that precisely, 20 21 and you know that, and a number of experts, and indeed 22 some of the clinicians, have tried to formulate their 23 view as to what they think it was. This was part of 24 that process. Now, I am looking at the transcript of the 30th, 25

starting at page 126. If I help to locate you in that 1 2 it's a series of questions that start from my learned friend Ms Comerton at line 10. She's talking about 3 recording the weight of the swabs and whether you timed 4 them, and Staff Nurse Mathewson says, no, you don't time 5 б them. 7 If we go down to line 18 question is: "Do swabs hold fluids other than blood?" 8 9 And the answer is: "There are six or seven figures there on the 10 left-hand column and they were saline soaks." 11 And she's asked to specify which ones they might 12 13 have been. And the answer comes: "39.8 down to 27.9." 14 15 And then she corrects herself and she says: "They are lines through them." 16 17 She refers to those assay line soaks. And when 18 she's asked over the page what that means, at 127, she 19 says: 20 "Whenever the kidney is put in place a theatre lamp 21 was overhead, so they were used to keep the kidney moist 22 while they were working in that area. So there was 23 saline on the soak or the swab already. So we have the 24 total weight." 25 Then if one goes down a little further to line 9:

"We used saline soaks, saline swabs that were
 soaked.

3 "Question: So they would be chilled or cooled 4 saline water?

"Answer: Cool."

5

6 So that's the issue that some of those swabs that 7 have gone into the count, if I can put it that way, were 8 not blood soaked but were saline soaked. What she did 9 is she used roughly 50 per cent.

10 In fact, if you look at that series that she's 11 talking about, 39.8 down to 27.9, all of which are 12 struck through, you can see just alongside them that 13 she's got half of that figure there. It's that 14 50 per cent that is attributable to blood loss and 15 that is how she gets her figure.

Do you have any observations to make on that at all in terms of trying to account for or monitor blood loss during the surgery so that you as a paediatric anaesthetist can be monitoring or managing, if I can put it that way, Adam's fluids?

A. Yes, in a general sense of view. Monitoring blood loss
is, first of all, very necessary to an anaesthetist
involved in any major operation where there may be some
bleeding. Having said that, it is actually very
difficult to get an accurate measure of the volume of

blood lost. Sometimes in major surgery there can be a significant bleed from a severed blood vessel and when that is the case, it can be more readily measured because one knows that that is blood.

5 Q. Mm-hm.

Broadly speaking, although the sheet looks untidy, they б Α. 7 have gone to some length, the nursing staff, to try and 8 allow for confounding factors such as other fluids being 9 mixed with what undoubtedly would have been a steady 10 trickle of bleeding as opposed to a torrential blood loss. So my general comment is that as records of 11 12 intraoperative blood loss go, this is actually quite 13 carefully kept in that they have made a real effort to 14 try and allow, as best they can, a factor into their 15 arithmetic for fluids measured which aren't blood.

16 Q. Would this have assisted you?

17 A. Yes.

18 Q. Thank you. I don't know if you have seen or read,

19 probably a better way of putting it, the transcript of 20 the evidence of Mr Keane, the surgeon?

21 A. Yes, I've read it.

Q. And he has addressed the issue of blood loss. There was an exchange as to whether it was significant and how much blood loss you would have to have to constitute significant. One of the things he said was, well --

I I think he couches it in terms that it wasn't particularly significant to the task in hand, in the sense that he did expect that there would be blood loss and then perhaps there wasn't -- I think what he's indicating is there wasn't much more than he would have expected for that kind of surgery on Adam with his history, if I can put it that way.

8 Can I ask your view, as the anaesthetist, did you 9 consider the blood loss to be significant, insofar as you can tell from the papers that you've read? 10 It was significant in terms that it would have to be 11 Α. 12 recognised as occurring and would have to be replaced by 13 the anaesthetist. It is not significant in that it is 14 not out of what one might expect for an operation such as this, given Adam's previous history. 15

16 Q. But it would have to be addressed?

17 A. It would have to be addressed, but it appears to me that 18 the blood loss during the operation was of the magnitude 19 that one would expect from such an operation in a child 20 such as Adam, who had had multiple previous surgical 21 interventions.

Q. Yes. Have you been able to detect from the papers that
you have seen any consequences or implications for the
level of blood loss that you think he did sustain?
A. Well, I've looked at several papers from several

different angles during the course of this exercise and 1 2 I think the simplest way of doing it is to look at his haemoglobin before he started. 3 4 Q. Yes. And his haemoglobin at the end of the operation, bearing 5 Α. б in mind that he received during the operation, I think 7 it was, 500 ml of red cell concentrate approximately. 8 I don't have the paper in front of me, and I can't give 9 the page reference, but --Well, I think we can help with the haemoglobin. 10 At Ο. least where it was at 9.30, which is at 058-003-003. 11 No. No --12 Α. That's where it is at 9.30. 13 Q. That's where it is at 9.30, but if we go back --14 Α. 15 THE CHAIRMAN: Were you going to make a general point about 16 the haemoglobin? 17 Α. I was going to make a general point in relation to the 18 blood lost in totality during the course of the 19 operation. MS ANYADIKE-DANES: Sorry. 20 21 So the haemoglobin was 10 point something or other Α. 22 approximately when it was measured on the eve of 23 surgery. Then again when it was measured 24 subsequently --Q. Sorry, we can help with that. 307-006-071. 25 If one

looks at the bottom chart, those are the blood results there, and you can see that the haemoglobin level at 7 o'clock is 10.5. At 9.30 it's 6.1. And at 11.30, it's 10.6. Does that help?

5 A. Yes.

6 Q. Thank you.

A. So we know that the haemoglobin at the start of surgery
before there'd been any blood loss was 10.5. At 11.30
when he returned to the intensive care unit it was 10.6.
So the concentration of haemoglobin in Adam's blood was
pretty much the same before surgery and after surgery,
which suggests to me that the volume of red cells given
back by Dr Taylor pretty much approximated to that lost.

Now, blood is transfused or -- it was transfused as 14 15 red cell concentrate, as opposed to whole blood, and the haemoglobin concentration of red cell concentrate, it 16 17 varies from unit to unit, but it's of the order of 20 to 18 24 grams per decilitre. So if one says that he got 19 500 ml of blood, that would be -- sorry, 500 ml of red 20 cell concentrate in terms of haemoglobin returned or red blood cells returned to Adam, that would equate to 21 approximately 1,000 ml or 1,000 -- or 1 litre of blood 22 23 which had been lost and the red cell components in it 24 had been replaced. So using that argument, I would suggest that a reasonable estimate for blood loss by 25

- Adam -- or from Adam during the course of his surgery 1 2 was of the order of 1,000 ml. Q. And given his size, is that -- and, therefore, I think 3 we were told 1,500 was his circulating blood; is that 4 5 a lot? His circulating blood volume would be 20 times 80, which 6 Α. 7 is 1,600. So 1,500/1,600 ml would be his normal 8 circulating blood volume. So you can see that 1,000 ml 9 is a significant proportion of his total blood volume and it would have been required to have been replaced 10 and it was replaced by Dr Taylor. 11 Yes. Then just finally, can you assist with the effects 12 Q. of that on Adam? It may be that we can look at the 13 14 blood pressure and the pulse and the anaesthetic chart 15 and see, it's 058-003-005. There's the anaesthetic record showing that, and I think we have a chart which 16 17 reduces it into a slightly simpler ... 18 In any event, are you able, looking at the actual 19 anaesthetic record itself, to see what effect that blood loss was having? 20 21 If we could perhaps scroll up to see the graphical part Α. of the chart. Thank you. If you look at the graph 22 23 at the bottom, the Vs is, if you like, they represent
- 24 the systolic blood pressure, which is the blood pressure
 25 within the arterial tree as the heart ejects, as it

1		contracts. We can see that it is pretty much around
2		about 100 and then latterly it begins to creep up,
3		perhaps for other reasons. But from this
4	Q.	Sorry, what does that mean, "perhaps for other reasons"?
5	A.	Well, we have discussed the possibility of raised
6		intracranial pressure developing during the course of
7		events. We have discussed the variability of depth of
8		anaesthesia for various reasons.
9	ο.	We're going to come to that.

There's a lot of things that can influence blood 10 Α. pressure during the course of an anaesthetic. The only 11 12 comment I think that can be usefully drawn in relation 13 to the question you've asked, which is the effect of blood transfusion on Adam in terms of blood pressure, 14 15 is that there is no doubt that Adam was not allowed to become hypovolemic during the course of the operation, 16 17 and I think to draw any further or deeper conclusion from that would be inappropriate, given the information 18 we have in front of us just now. 19

Q. We can pull up a chart showing all his vital signs in
case that discloses anything further. 307-006-063.
It's the top chart, chart 1, which shows his heart rate,
blood pressure and so forth.

A. So this is a chart that has been prepared by the inquirywith a tabulation form of an anaesthetic.

Q. Yes. Of those numbers, yes, but just so you can see 1 2 them all together along side the times. Does that show anything that can be attributed to the fact that he had 3 4 lost that amount of blood and had that amount of blood infused? 5 I think I would hold by what I've just said, that б Α. No. 7 his systolic blood pressure has never significantly --8 has never decreased to a point which could be 9 attributable to hypovolemia, and the only cause of 10 hypovolemia would be failure of the anaesthetist to keep up with fluid or blood administration into Adam's 11 12 circulation. That didn't happen, as far as you can see from the 13 Q. 14 evidence? 15 A. No, there's nothing to suggest that happened. One thing 16 I might add is that had an accurate central venous 17 pressure been available, it might have shown something 18 different, but we don't have that information. 19 Q. Yes. What could an accurate central venous pressure be showing that one wouldn't be gleaning from this? 20 21 Α. If I could take an example perhaps there from a different setting. 22 23 Q. Yes. 24 Α. If you have, for the sake of argument, a child of Adam's age and weight who was having a major operation of 25

a different kind and there was bleeding, it may well be 1 2 the case that the blood pressure would be sustained because of the body's reflexes to maintain perfusion 3 pressure to vital organs. But the actual volume of 4 blood within the child's circulation would have 5 б diminished significantly and that would be reflected by 7 a decrease in central venous pressure. Okay. If we go back to the anaesthetic record, I'm 8 Q. 9 going to move on now to deal with the issue of

10 atracurium. If we go to the anaesthetic record, one can see at 058-003-005 -- well, it's in Dr Taylor's 11 12 handwriting. It's just the first three typed 13 administrations of drugs on the far left side. Then 14 immediately below that is what we understand to be 15 atracurium, and you will see -- and we'll pull up a chart where it's easier to see the exact times, but in 16 17 any event, that's it being administered over the course 18 of the surgery.

19 Then if we go to 058-003-008, here's the chart which 20 shows a number of things. You see the anaesthetic 21 agents. Then if you look to the right-hand side, 22 halfway down, you see relaxants, and then one sees 23 atracurium there and the box is ticked. So that's the 24 form of muscle relaxant that was being used with Adam. 25 Then if I pull another piece of information so that

we just all have it conveniently, maybe we can see if we can get these alongside. 307-006-063. There we are. It's really the bottom one. If you look, these are the drugs that were administered to Adam along the left-hand side is the time, and you can see atracurium at 10, at 7, 10 at 7.30, 10 at 8, 5 at 8.30, 10 at 9.30 and nothing further.

8 If we look at it in a slightly different way, along 9 with other things that were going on, by looking at 10 a graph at 307-006-064, there we are. You can see along 11 the bottom the drugs and including there the atracurium. 12 And you can see in relation to everything else that's 13 being administered when the atracurium is recorded as 14 having been administered.

You see there at 9.30, that's the lastadministration of it, and the operation continues on.

I should say that that chart and this graph, these are documents that were compiled by the inquiry's legal team just to try and find perhaps a more accessible way of presenting the information.

21 Now, the first thing I would like to ask you is, we 22 know it's a relaxant because the box is ticked, but what 23 is the purpose of the atracurium?

A. The purpose of atracurium is twofold. Would you like meto elaborate a bit about the nature of the drug?

1 Q. Yes.

2 It's a neuromuscular blocking agent, which is Δ synthetically made. The original prototype, if you 3 like, is a naturally occurring curare. It acts at the 4 5 neuromuscular junction and it blocks the transmission of a signal from a motor nerve to a muscle to contract. 6 So 7 if the appropriate receptor sites on the muscular side of the junction are occupied by an atracurium molecule, 8 9 the muscle is no longer able to respond to a neural stimulus to contract. 10

The purpose of giving a neuromuscular blocking agent 11 is very broadly speaking twofold during an anaesthetic. 12 If it is a major procedure such as Adam underwent, then 13 14 he would have required to have been artificially 15 ventilated, and that necessitates the placing of a tube in his windpipe. To do that, the anaesthetist has to 16 17 visualise the larynx and pass a plastic tube through his 18 mouth through his larynx. Even with a significant depth 19 of anaesthesia, the muscle tone and contraction and reflexes make that quite difficult to do unless muscular 20 21 activity is abolished. First of all, it allows the anaesthetist to complete that part of the anaesthetic, 22 which is very near the beginning of the whole procedure. 23

24 Part of that allows the patient to be ventilated25 without any reflex, coughing, bucking, moving. So the

first requirement for a muscle relaxant is to allow the anaesthetist to secure the airway and safely ventilate the patient for the duration of the procedure.

The second reason to give a neuromuscular blocking agent is to allow relaxation of the muscles when, if it's an abdominal operation, in the abdominal wall. If a surgeon is operating on a structure deep inside the body cavity, any tension in the muscles of the abdominal wall which have been incised will render access to the operative area difficult.

So a neuromuscular blocking agent is continued, 11 certainly for an operation where a body cavity is opened 12 for the duration of the operation, to improve the ease 13 14 of access of the surgeon to the operative area. And 15 those, broadly speaking, are the two reasons why a neuromuscular blocking agent is given at the beginning 16 17 and during an operation where a body cavity is opened. 18 Q. You were asked to provide a report dealing with the 19 administration of atracurium. That's correct, isn't it? That is correct. 20 Α.

Q. Yes. And the issue of atracurium was actually -- we're trying to find the precise reference for it -- raised during the experts' meeting of 9 March. The issue of the drugs that were administered to Adam was raised during the experts' meeting on 9 March.

1 A. Yes.

2 Q. You've seen that transcript?

3 A. Yes.

Q. There was a discussion about all the drugs that he was given and atracurium in particular, and I'm trying to find -- I think my learned friend probably has that reference -- it now, where that's discussed. It's right towards the end.

9 MR UBEROI: I'm afraid I don't have the inquiry pagination.
10 It's page 132 of my transcript, but I don't know how
11 it's made its way into the inquiry's bundles.

MS ANYADIKE-DANES: We're trying to see if we can find it for you.

14 I think it has come up.

MR UBEROI: It starts at page 132, which is obscured there, and then there's a passage which goes on, broadly

17 speaking, up until page 135.

MS ANYADIKE-DANES: If we start, I think it's at 18, you've been asked the question about -- well, I have asked you the question as to one is called Atrac, what is that for? And so then you start and you're going from left to right on the drug sheet to actually explain what all the drugs are.

If we carry on from that, I think there's -- the next page. Yes. It starts with the query -- pick it up

at line 14, and then you start with your answer at line 1 2 15. You say what it's an abbreviation for, that it's a muscle relaxant, a sensible choice and why it is 3 a sensible choice. 4 Then I say that I'm going to ask what the effect you 5 б think any of these things contributed to his 7 presentation or his condition, but the Atrac, though, 8 was given, it would appear, five times periodically and 9 it doesn't appear to have been given again after 9.30. And the question is posed: why would that be? 10 And you pick up your answer: 11 12 "If you give a dose of atracurium sufficient to 13 cause neuromatic blockade adequate to allow intubation 14 and surgical incision to take place, the duration of 15 action is about 20 minutes to 30 minutes." And I ask: 16 17 "Does that mean they are topping him up?" As you see the administration of it, and you say 18 "Yes". 19 20 And then I ask: 21 "Well, why wouldn't they be topping him up after 9.30? 22 23 And then you say: 24 "Well, it verges on speculation." Can we go to the next page, please?: 25

"The perceived need to top him up. One would 1 2 imagine that the surgeon was reaching the end of the operation. I can't remember the exact time but it would 3 4 be 10 o'clock onwards. But one would speculate." I tell you that roughly the time of anastomosis is 5 б 10.30. You say: 7 "Well, they would be closing up at around 11." 8 Then I ask you so effectively what about 9.30? 9 And you say it's speculation, and I invite you not to speculate if you don't want to. 10 Then you go on to say: 11 12 "Because there wouldn't have been any perceived 13 need. There is usually a surgical plea for: can I have 14 some muscle relaxation when closing an abdomen, 15 particularly if a large organ has been -- an adult size organ would have been transplanted." 16 17 So I ask you: "Does that mean surgeons usually want it? 18 "Answer: Yes. 19 20 "Question: If the closing up happened some time 21 round about 11, when would you be given it to permit -- " 22 And then you say: 23 "You would be trying as an anaesthetist not to give 24 it because the patient won't breathe at the operation because you have given it, but the surgeon wants at that 25

point in time to assist with muscle closer."

2 A. Closure, it should be.

3 Q. "However, fortunately there was none given since the 9.30. So when it comes to saying Adam didn't breathe at the end of the operation I think you can discount the effect of atracurium."

7 And unless my learned friend tells me to the
8 contrary, I think that's pretty much the end of the
9 discussion on atracurium.

MR UBEROI: It goes on to the next page, 135, please. Your final remark in the middle of the page:

12 "Now, I think you can sum this up by saying that you 13 cannot read any significance from the drugs used during 14 the course of anaesthesia, including his epidural

15 anaesthetic."

16 THE CHAIRMAN: Thank you.

MS ANYADIKE-DANES: Then I ask whether anybody else agrees or disagrees, and people say either they do agree or it's not in their area, but effectively nobody raises anything about atracurium and its mode of -- well, not its mode but its pattern of administration.

That is an issue which was partially raised with Dr Taylor and, as a result of that, we asked you to provide a report, and we asked Dr Taylor to provide a statement. You provided your report without the

benefit of Dr Taylor's statement. He provided his
 statement without the benefit of your report. So
 they're independent entirely.

I wonder if we could go to Dr Taylor's statement 4 now. I don't have a paginated version. 5 б THE CHAIRMAN: It's witness statement 008/7. 7 MS ANYADIKE-DANES: Thank you. If we go there and we see at 8 the next page, which would be page 2 of that, it's 9 recited for him what the anaesthetic record shows and where that comes from. Then he's asked to explain the 10 purpose for which atracurium was administered to Adam 11 and why that particular drug was used. 12

He goes through essentially, I think, what you have said, which is that it's a neuromuscular blocking drug. It's short acting, around 20 to 30 minutes, and so on. You would agree with all of that?

17 A. Yes.

Q. Then we've asked what determined the dose at which it was administered to Adam, including why it was administered at 10 milligrams at 10 o'clock, 7.30, o'clock, and 9.30, but 5 milligrams at 8.30. And you see the answer there. You say: "The recommended dose is 0.3 to 0.6 milligrams per

24 kilo. Adam was around 21 so the dose given was within 25 the recommended range."

1 He said:

2 "It was administered at the beginning of anaesthesia to assist with intubation of the trachea." 3 Which I think is pretty much what you were 4 explaining in your evidence: 5 б "And it was given throughout the surgery to prevent 7 unwanted muscle movement especially in the diaphragm or abdominal muscles." 8 9 I gather you would agree with that, that would be a reason to do it? 10 Yes. 11 Α. 12 Q. And then --13 THE CHAIRMAN: Sorry, rather than read through the 14 statement, is there any point in this section about the 15 dose or the next section about the times with which you 16 don't agree? MS ANYADIKE-DANES: Well, just for the benefit of those who 17 would be trying to follow the evidence who wouldn't 18 necessarily be able to pick that up in that way, if they 19 20 were reading the transcript on the website, if I may 21 just give a little bit of the salient points. 22 THE CHAIRMAN: Is the witness statement available on the 23 website? 24 MS ANYADIKE-DANES: I'm not sure it is at the moment. 25 THE CHAIRMAN: It is.

MS ANYADIKE-DANES: Well, perhaps you can read it through 1 2 and ... If I may take you to page 3 because I'd 3 particularly like to take you to that: "I don't remember why the subsequent doses were 4 given." 5 That's the one after 7: б 7 "But the reasons would be to prevent unwanted muscle activity." 8 9 And in the knowledge of the activity of the duration of 20 to 30 minutes. 10 Can you help with why you would give 10 milligrams 11 at the intervals that he did and then give 5 milligrams 12 13 at the time that he did? What is your understanding of 14 such a pattern of administration of dose? 15 MR UBEROI: If I might interrupt, if someone were to be following it on the website they would have missed his 16 17 explanation there, which is very clear, which is as 18 a matter of clinical judgment based on, I think, at 19 least two clear reasons he's given there. Either his judgment as to muscle movement. 20 MS ANYADIKE-DANES: Yes, you're quite right. 21 22 MR UBEROI: So the reason has been given and it is perhaps 23 for the witness to comment whether he agrees with it or 24 not. MS ANYADIKE-DANES: Yes, you're quite right. I was trying 25

1 to be shorter, but anyway perhaps it's fairer to put it
2 out like that:

3 "To prevent unwanted muscle activity or to assist 4 the surgeon once the surgeon has commenced with the 5 knowledge of its duration of activity of 20 to 30 6 minutes."

7 Is why he would have done it. And then he says:
8 "I cannot remember the reason for its administration
9 as 9.30, but I would have been exercising my clinical
10 judgment or for any of the reasons I have stated
11 before."

12 And he reasons that he's stated above is to do with 13 not wanting any unwanted muscle activity. So it's 14 a combination of not wanting muscle activity and 15 exercising his judgment as to whether he's likely to 16 have unwanted muscle activity or a surgical request.

17 So those are the reasons he says. And there's been 18 no evidence of the surgeon requesting it. So if one's 19 with exercising his judgment so as to achieve a situation where there is no unwanted muscle activity, 20 21 if that's what Dr Taylor was trying to achieve, can you help with why you might have a pattern of 10 milligrams 22 23 administered at 7, 7.30, 8 o'clock, then 5 milligrams at 24 8.30 and then an hour and 10 milligrams at 9.30? Could I ask you to put up the report that I prepared 25 Α.

1 in relation to this? It may help.

2 Q. Yes. Perhaps the best place to start is

3 page 204-014-002.

MR UBEROI: Well, while that's being brought up, may I add for completeness the remark about no evidence of a surgical request I accept there hasn't been not been any evidence about surgical requests, but it's because it's not been asked because of the way this issue has arisen. So I think that's putting it slightly more clearly for the witness, if I may say.

11 MS ANYADIKE-DANES: Yes. We may have to address that.

12 This is your report then. Using that or anything 13 else that you want to say, can you help with the pattern 14 of the administration of the dose initially? 15 A. Okay. Can I preface this by just quoting from the 16 summary report that I prepared on 18 March? When 17 I said -- I was asked to comment on the anaesthetic 18 given by Dr Taylor, and in that, I said:

19 "Appropriate anaesthetic agents were used."
20 And at that point there's no discussion over the
21 dosage pattern, other than to exclude the presence of
22 a neuromuscular blocking agent at the time of the end of
23 the operation. This issue has arisen subsequent to
24 that.

25 Q. Just before we leave that, the issue -- this issue --

may have arisen subsequent to that, but what he was actually administered is something that happened on 27 November and is recorded, and it was there for consideration. The point itself was raised during the experts' meeting on 9 March. So I don't think, Dr Haynes, it's entirely right to say there's been no issue raised about it?

A. That is true, but the emphasis was a little different
during that discussion and, forgive me if there's been
a slight misunderstanding, but I believe I've fully
addressed it in this report now, which we have in front
us.

Yes. Well, except to say that I think that there may be 13 Q. 14 an issue as to why, if you expressed the view that you 15 had no comment to make or the anaesthesia was entirely satisfactory, including the epidural, why you could 16 17 express a view like that without having considered the actual dose and pattern of the various anaesthetic 18 19 agents and relaxants. That presumably is part of what 20 you would have been looking at to have formed the view 21 that you had no adverse or other comment to make about 22 the anaesthesia.

A. No. Would it help perhaps if we just discussed this --Q. Yes.

25 A. I have tabulated in the middle of this page, as you have

- done, the doses given and noted that none -- that the
 last does was given at 9.30.
- 3 Q. Yes.
- A. And looking at the other documents available, it appears
 that the closure of the surgical incision is unlikely to
 commence prior to 10.30 at the earliest.
- 7 Q. Yes.

Forgive me, but it was possibly an omission during the 8 Α. 9 original discussion, but this has now been fully 10 addressed as to an examination of the dosage pattern. MR UBEROI: In fairness to the witness, I think there might 11 12 be some confusion emerging, and I appreciate the way 13 it's being put and I appreciate the way the witness is 14 trying to answer it. But on my reading of his report, 15 it may well be there is still an issue with the decisions taken as to the administration, for example, 16 17 this muscle relaxant during the surgery, and rather this 18 new report is more aimed at engaging with a separate 19 issue as to the precise timing of brainstem death. So 20 I would not want the witness to feel it was necessarily 21 being put to him that it was agreed that there is now 22 an issue, from his point of view, with the 23 administration of this drug, when, in all fairness, 24 there may well not be.

25 MS ANYADIKE-DANES: Why don't we hear his evidence? What

I'm putting to him first, before we get into the issue 1 2 of brainstem death, before we get into the issue of why nothing was administered after before 9.30 in terms of 3 atracurium, the first question I'm asking is why in 4 those intervals is it 10 milligrams and then you've got 5 б a dosage of 5, and why do you have half hourly intervals 7 and then you have an hour space? That's the first point 8 I want to deal with before we deal with what happens 9 after 9.30.

Okay. First of all, when an anaesthetist records dosage 10 Α. of a drug such as atracurium, it is so commonly used 11 12 that the individual may not actually note the time it was given. Secondly, I can't understand why Dr Taylor 13 14 or whoever was working with him chose to give an 15 increment of 5 milligrams rather than 10 milligrams. What might be an anaesthetic reason, if I can put it 16 Q. 17 that way, for doing that? 18 Α. A very simple, a really simple reason is there may have 19 only been 5 milligrams left in the syringe that 20 contained the drug, and to give more would have meant 21 opening another vial, which sounds very trivial, but if 22 there is a problem with muscular tone, a dose of 23 5 milligrams could easily resolve it while another 24 syringe-full is drawn up and made really. As simple as that, is the answer. 25

1 If you were to look at a wide range of anaesthetic 2 charts for children ventilated, of a size like Adam, 3 during an operation, you might find that some 4 anaesthetists give 10-milligram increments, some might 5 give 5, some might give more. The actual dosage is --6 the dose given at any one time is in all honesty 7 somewhat idiosyncratic.

8 What I think is important is we note that an 9 adequate dose was given at the start of the procedure 10 and in relation to, was there any effect of atracurium 11 at the end of the operation? Was too much given such 12 that the effect persisted beyond the desired time? And 13 as you'll see I say no --

14 Q. Well, now that's coming on to, why was nothing 15 administered after 9.30?

16 A. Yes.

17 Ο. But just so we have your thoughts, the explanation -- or 18 in your view, an explanation for the pattern of amount and interval of the administration prior to 9.30 is 19 simply you start off with a dose that will achieve the 20 21 desired effect right from the outset and then it's 22 really a matter, as I think Dr Taylor said, of judgment 23 for how much topping up you do and when you do it, 24 recognising the size of the child and the effect, how long it takes the effects to wear off. 25

- 1 A. Yes, that's correct.
- 2 Q. Right.

3	A.	And it can be achieved with greater precision if the
4		anaesthetist chooses to give it by continuous infusion,
5		but that is another layer of complexity which is
б		necessary.
7	Q.	Can I ask how it actually is administered? Sorry,
8		can you tell from the evidence here how it was
9		administered?
10	A.	It was administered by Dr Taylor or his assistant taking
11		a syringe containing the drug, connecting it to Adam's
12		drip, his intravenous line, and injecting a known volume
13		into the fluid which was being administered to him.
14	Q.	Thank you. Sorry, then, now I think you're going to
15		help us with why, in your view, no further atracurium
16		was administered after 9.30.
17	A.	Yes. I've put forward several possibilities, and if
18		I may go through them?

19 Q. Yes.

20 A. First of all --

21 MR UBEROI: Sorry. So this question is perhaps put in 22 a clearer sphere, is the question -- is the witness 23 being asked to give his view as to why there was no 24 clinical need or clinical indication for the further 25 administration of atracurium after 9.30? Which I think

1 might be a more sensible way of putting the question to 2 the expert, if I may say.

MS ANYADIKE-DANES: I think it might amount to the same 3 4 thing. What I want him to express is why, in his view, from an anaesthetic point of view, you might not require 5 6 any further administration of atracurium after 9.30. 7 And he's going to go through, as I understand him, the 8 various reasons why you might or you might not. 9 MR UBEROI: I just repeat, if I may, with the witness having 10 agreed it's a matter of clinical judgment, in his view -- the question is surely, in his view, why would 11 clinical judgment --12 13 THE CHAIRMAN: Were we not referred to the second Newcastle 14 meeting at which he said the choice of drug was entirely 15 sensible and you would be trying not to top him up after 10 o'clock and trying not to give it after 9.30? 16 17 MS ANYADIKE-DANES: I think perhaps it would be better if 18 the witness answered that because I'm not entirely sure

19 that that is what he was saying at the meeting.

But in any event, you have the point, you're being asked for your view as an expert anaesthetist as to the reasons why you might not prescribe any atracurium after 9.30 in this surgery. It's his view, Mr Uberoi.

24 I think he can give his view.

25 MR UBEROI: Well, again, it would be my opinion that the

1 question should be phrased along the lines of: what 2 factors affect the anaesthetist's clinical judgment as to why atracurium wasn't in fact given after 9.30, the 3 9.30 dose having worn off at 10? 4 MS ANYADIKE-DANES: I'd first like his view as an expert. 5 Which question am I to answer? б Α. 7 THE CHAIRMAN: Your question, Ms Anyadike-Danes is? MS ANYADIKE-DANES: Why, in his view, might you not 8 9 administer atracurium after 9.30 in this surgery? 10 THE CHAIRMAN: We have your view --MS ANYADIKE-DANES: He hasn't answered that. 11 12 THE CHAIRMAN: I'm sorry. He has said that -- well, there's 13 no evidence if there was a surgical request, but that 14 leads back to a point about this issue not having been 15 raised previously. 16 MS ANYADIKE-DANES: Yes. 17 THE CHAIRMAN: If you're expressing a view on why it might not be administered after 9.30, how speculative is your 18 19 answer to that question to be? A. It's going to be more -- with more certainly than 20 21 speculation but it is not going to be with certainty, if 22 that makes sense. 23 THE CHAIRMAN: What would be ... So you're being asked to 24 give a clinical -- well ... 25 Can I give my answer and then you can perhaps take it Α.

1 further if you wish?

2	THE	CHAIRMAN: Okay. Answer as clearly as you can what
3		would affect your judgment as to why this drug would not
4		be given after 9.30.
5	MR U	JBEROI: [Inaudible: no microphone] then you avoid the
б		query, the speculation. And if it's put like that, then
7		I think it's a far more appropriate way for it to be put
8		to an expert.
9	THE	CHAIRMAN: Okay.
10	Α.	You want me to answer my view as to why it was not given
11		after 9.30?
12	MS A	NYADIKE-DANES: What would affect your judgment?
13	MR U	JBEROI: Your clinical judgment after 9.30.
14	Α.	The first thing is to assume that what is written on the
15		anaesthetic chart is absolutely correct and that nothing
16		has been omitted.
17	Q.	Mm-hm.
18	Α.	Given the detail on this chart, I think it unlikely that
19		anything has been omitted to have been recorded. It's
20		a detailed record of what was given and what happened,
21		so I think it would be safe to put that to one side.
22	THE	CHAIRMAN: Because it's not obviously lacking in
23	Α.	It's not lacking in other areas so it's unlikely to be
24		lacking in this area. The next part of my answer
25		is that I am surprised that no further muscle relaxant

was given beyond 9.30, given the fact that wound closure
 would have been taking place starting at around 10.30.

Also given that it might have been a little difficult to close the wound, given the fact that an adult or certainly adolescent-sized kidney was being implanted. So there would need to have been some muscle relaxation present at the time of wound closure.

The reasons why further -- or the prompt that would 8 9 have resulted in Dr Taylor or whoever was with him giving further doses of muscle relaxation would have 10 been comments from the surgical team about the lack of 11 muscle relaxation, the patient may have begun to cough 12 and gag on the endotracheal tube, which would be another 13 14 prompt, or many anaesthetists will simply give a bolus, 15 that's an incremental dose of a neuromuscular blocking drug, at regular intervals throughout a long operation 16 17 without waiting for those prompts.

18 What I cannot dissect out from information given is 19 whether the atracurium was given by rote, pre-empting 20 any requests or clinical signs, or in response to any 21 particular sign or stimulus evident in Adam.

The next thing that I think one can with a degree of certainty conclude from this pattern of drug administration is to say that beyond 9.30, there would have been no prompt either in terms of signs visible to
Dr Taylor from Adam or verbally from the surgical team 1 2 that the effect of the previous doses of atracurium were 3 no longer evident. 4 MS ANYADIKE-DANES: You say that because if that had been the case, he would have administered it? 5 б Yes, and given the otherwise completeness of this Α. 7 record, I think it very unlikely that it would have 8 merely been forgotten to have been put down in the 9 document. Q. And why might there be no prompt? 10 A. Because there was no muscle tone, because there was no 11 12 coughing on the endotracheal tube, and muscle tone was 13 such that there was no visible need to give a further 14 dose. And I anticipate that your next question is going 15 to be, why is that the case? 16 Yes, it is going to be: why that is the case? Q. 17 A. Well, there are two possible explanations that I can 18 offer you. One is if one takes the assumption that the 19 neuromuscular blockade was given pre-emptively by rote, that in fact the epidural anaesthetic and the Halothane 20 21 anaesthesia provided adequate muscle relaxation for surgeons to work in the surgical field, regardless of 22 23 the fact that he was or wasn't given atracurium. 24 The second alternative view is that Adam was no longer able to provide or to give signs such as reflex, 25

gagging, coughing on an endotracheal tube, or increase
 in muscle tone in response to surgical stimulus in the
 operative wound.

4 THE CHAIRMAN: And he would no longer be able to give those
5 signs if the catastrophe had already occurred?
6 A. That is correct.

7 MS ANYADIKE-DANES: Now, that's actually very helpful, the 8 way you framed it, because I think you put it slightly 9 differently in your report, and I think that people wanted some clarification about that. If you go to 10 204-014-003, in fact it starts really on the page --11 it's before that. What you're doing is you're listing 12 out the possibilities, and you've given the one that 13 14 actually everything had been done in a certain way, just 15 not recorded, which you discount.

16 Then you have that an excessive dose had been given 17 and, therefore, he didn't need any more after 9.30, and 18 you don't seem to think that is relevant or occurred.

19Then the Halothane anaesthesia combined with the20epidural nerve blockade produced adequate muscle21relaxation for the surgical field, which is one of these22last two options that you have just given evidence on.

23 You said:

24 "This is a possibility but the question is then25 asked whether the previous repeated doses were given

pre-emptively by rote, as is often the case, or because of increased muscle tone in the operative field or coughing in response to the tracheal tube stimulus."

And before we go to the fourth one, let's just stick
with that for the moment.

6 If it was given by rote, why would you stop at 9.30?7 A. Well, you wouldn't.

8 Q. Right. Then if we go with your fourth one, that Adam
9 had suffered brainstem death by the time the abdominal
10 incision was being closed:

II "It has to be noted that following brainstem death reflex muscle contraction can still take place in response to noxious stimulus. The reflex is purely at a spinal level. However, the usual situation at this point is complete loss of muscle tone."

Now, just so that we understand you, leaving aside whether he was sort of gagging and coughing on this tracheal tube and stick with the muscle tone, what is it that an anaesthetist would be able to detect when you say a loss of muscle tone? What happens?

A. In response to surgical operation, it would become
visibly difficult for the surgeon to sustain exposure of
the operative field within the body cavity.

24 Q. I mean, just what happens?

25 A. When --

Q. When you say it became visibly difficult, what is it 1 2 you're seeing? Tense muscles in the abdominal wall or the chest wall. 3 Α. Q. Contractions? 4 5 A. Yes. б Okay. In terms of his other muscle tone, since Q. 7 Dr Taylor -- not in the abdominal cavity, he may not 8 actually have been seeing that, so what is it that 9 an anaesthetist did actually detect when one's talking 10 about a loss of muscle tone? A. Lack of movement, no resistance to movement. 11 12 Q. Right. 13 Soft muscles that aren't contracting. Α. 14 Okay. So leaving aside the gagging, that is something Ο. 15 that you think that an anaesthetist would be able to detect if that was happening? 16 17 A. Easily. Q. Easily. Is that part of the stimuli that the 18 anaesthetist is looking for to guide him as to whether 19 20 he should be topping up or administering any further 21 dose? 22 A. Yes. 23 Q. And if he doesn't see it, then he --24 A. There's no prompt, there's no visual prompt to do so. 25 That's fairly clear. Then you go on to give a bit in Ο.

1 italics as to your opinion as to what is the most likely 2 reason.

But I think we need to be very clear here. All of these scenarios or possibilities as to what might have happened and the reason why that might be, that is your view looking at the information? You're not trying to say, are you, that that's something that Dr Taylor thought? This is your view?

9 A. That is my view given the information available to me10 after giving it a great deal of consideration.

11 Q. And you have there expressed what you think is the most 12 likely reason?

13 A. I have.

14 Q. And your most likely reason is what?

15 That Adam beyond 9.30, or certainly beyond 10 o'clock, Α. when the last dose of atracurium's effect would have 16 17 gone, was no longer in a position to be able to cough on the endotracheal tube and had lost abdominal wall muscle 18 19 tone, because at this point perhaps brain dysfunction 20 might be a better term than brain death, but certainly he was not, in my opinion, neurologically capable of 21 22 demonstrating these signs which are invariably present 23 during the course of an anaesthetic for an abdominal 24 operation.

25 Q. I understand that. When you were explaining about the

1 loss of muscle tone, you say that is something that 2 would be -- I think you said readily apparent, or something close to that description, to the 3 4 anaesthetist. Is that something that anybody who was handling Adam or close to him would be able to detect? 5 б Α. Yes. 7 Q. A medical person, I mean. 8 It needn't be medical. The surgeon, the surgeon's Α. 9 assistant, the scrub nurse, the anaesthetic nurse would 10 all be capable of providing cues, prompts, if they noticed these things. 11 12 Q. What you mean by that, so we're absolutely clear, is 13 they would all be capable of appreciating that if that 14 had happened, that that is what had happened, that there 15 had been a loss of muscle tone? A. No. If there was normal muscle tone at a point where 16 17 further muscle relaxation would be required, they would 18 easily turn round and say, "Dr So-and-so, this is a bit 19 tight, he's coughing", you know. The cues for further 20 administration of muscle relaxant would easily be picked up by any member of the operating team. 21 22 Thank you. Q. 23 THE CHAIRMAN: Just to get that clear, what would be 24 detectable to all the doctors and the nursing staff is 25 the need for a further dose of atracurium?

1 A. Yes.

2 THE CHAIRMAN: Not the fact that there seems to be a level of neurological inactivity? 3 4 Α. Yes, that's correct. 5 THE CHAIRMAN: Well, if this is right and there wasn't б neurological activity, to whom would that be apparent? 7 Α. The fact that there's no neurological activity I think 8 didn't become apparent until the end of the operation 9 when Dr Taylor found that Adam was unable to breathe, cough and that brainstem reflexes, in terms of response 10 to light by his pupils, were absent. 11 12 MS ANYADIKE-DANES: Sorry, I wonder if I could put it this 13 way, because it was a question I wanted to follow up on 14 and I hadn't put it well the first time you answered it. 15 You have described the fact that if the patient requires further muscle relaxant, you can see the muscles start 16 17 to constrict a little bit, maybe there's some coughing. 18 You can see those and you described those as prompts for 19 muscle relaxant. I think your view was that any of 20 those nurses there, the scrub nurse, the anaesthetic 21 nurse, any of the assistants or the surgeons, that is something they would all be able to see? 22 23 Α. Correct.

Q. When I was asking you prior to that about something thatI called the loss of muscle tone, and maybe that's the

1 wrong expression to use --

2 A. No, that's correct.

I was asking you how that would manifest itself and you 3 Ο. said, well, he'd be floppy and you described -- maybe 4 you should describe in a little more detail, because 5 б I think what I would like to know is whether -- leaving 7 aside whether you would notice the prompts and the cues 8 for the requirement of further muscle relaxant, who, if 9 anyone there, would be in a position to notice that he had got a loss of muscle tone? 10

A. I think it would be very unusual for anyone to actually
comment or note on the loss or the fact that muscle tone
wasn't present.

14 Q. No, who would be in a position to notice that that had 15 happened, not whether they would comment on it or not, 16 but whether they'd be in a position to appreciate that 17 that had happened?

18 A. I think for someone to appreciate it, that it had 19 happened, they would have to be actually asked the 20 question at the time. But the people who would be able 21 to ascertain that, had the question been for discussion 22 at the time, would be the surgeon, the anaesthetist and 23 possibly the scrub nurse if he or she was suitably 24 experienced.

25 Q. If he's floppy, how does that floppiness manifest

1 itself?

2	Α.	If I can perhaps answer it with the converse. If
3		you have an injury to the abdominal wall or abdomen,
4		you will walk around with your muscles tense. If you're
5		floppy with no muscle tone there, there is no reflex
б		muscle contraction when retractors are placed in the
7		wound, there is no spontaneous movement, the limbs adopt
8		a neutral position, and the head, as defined by the
9		effects of gravity.
10	Q.	So what is the effect of the appearance of a loss of
11		muscle tone on the one hand and a muscle that is relaxed
12		through the use of muscle relaxant?
13	A.	No difference.
14	Q.	They would appear the same?
15	A.	Yes.
16	Q.	Thank you. In your view, if you had noticed something
17		that allowed you to form the view that no further muscle
18		relaxant was required for the reason that you have
19		given, which is your fourth scenario, as an anaesthetist
20		in the operation what do you do at that stage?
21	A.	The first thing you would do is try and ascertain what
22		is actually happening. If I was in what would be
23		a hypothetical situation, I hope, where I'm worried that
24		a patient has no muscle tone in the abdominal wall,

1 neuromuscular blocking drug had been given, I would 2 satisfy myself that any other agent hadn't been administered excessively such that it would cause 3 a depth of anaesthesia, which again may produce the same 4 effect. I would look as the first point of examination 5 at the patient's pupils. That would include retracting 6 7 the eyelid, shining a bright light into the eye and observing to see if there's any reflex contraction of 8 9 the pupils.

10 Q. Adam's eyelids were actually taped, we know that from 11 the anaesthetic record, so you'd just remove the tape 12 and do that?

13 A. Absolutely.

24

14 Q. What would you do then?

15 Then I would start to begin to wonder what had happened, Α. 16 what was causing this. It would be a terrifying finding 17 because the implication is that something dreadful has happened to that patient, and at that point in time 18 19 it would be very hard to know exactly what has happened. In the situation -- I know that the only thing that 20 21 one could do would be to ensure that the operation proceeded to as timely a conclusion as possible, if 22 23 I was ... If I felt concerned that a major neurological

25 the general anaesthetic, effect of the Halothane. If

82

event might have happened, I would consider withdrawing

once the general anaesthetic effect of the Halothane had been removed and I was happy that no other drugs with a serious or major sedative effect remained in the circulation, that would give information that something was far amiss.

6 Q. How long would it take to reverse that or withdraw the7 effects of that?

8 A. The Halothane?

9 Q. Yes.

If I can put it into context. If a patient is 10 Α. ventilated for an operation and Halothane is a drug used 11 12 and, let us say, it is a three or four-hour long 13 operation, it may take 15 or 20 minutes for the effect 14 of the Halothane to disappear. Halothane is mostly 15 removed by being exhaled from the patient's lungs, some of it is removed by the liver, but the -- it's 16 17 a relatively long duration so 15 to 20 minutes before you could consider that the effects of Halothane had 18 19 been removed. And there is a clue -- more than a clue, there is a guide as to how much Halothane is present 20 21 in that there's a gas monitor and the gas monitor was 22 used in Adam's case. Once the exhaled concentration of 23 Halothane or any other volatile anaesthetic was at or 24 near zero, then the effects of that could be -- the presence or absence of it could be monitored and the 25

presence or absence of any anaesthetic effects could be
 assessed.

Q. Before we got to the issue of why atracurium hadn't been administered by Dr Taylor after 9.30, in his evidence Dr Taylor did give evidence about the lightening of anaesthesia and just what his general pattern would be coming towards the end of surgery. You can find that in the transcript of 20 April. It starts at page 123.

9 To give the context of it, he talks about -- he 10 starts right at the top really at 2. I'm asking him 11 about when you heighten up the anaesthesia and try to 12 bring him round, where does that happen? And he says it 13 happens in the operating theatre, and then in advance of 14 the wound closure.

15 Then he goes on down that page and he talks -there's a bit of an issue as to whether Adam did or did 16 17 not have sterile towels over his face. The fact of the 18 matter is that Dr Taylor just can't remember. He says it would have been his practice not to put sterile 19 towels over his face but that doesn't appear to be how 20 21 it's recorded. In any event, he doesn't remember so 22 that's that.

23 What he does say is:

24 "But I would be looking at his vital signs ..."25 If we go over the page:

"... to look at his face and his pupils and to see
 signs of recovery from his anaesthetic."

3 So that's what he's doing, he's starting to lighten
4 him, and he puts that process as before the wound
5 closure he's starting to lighten him.

6 Now, in the course of lightening a patient in that 7 way, I presume you understand the process as he's 8 talking about it? In the course of doing that and 9 examining Adam as he described he did, if Adam had 10 suffered a loss of muscle tone, could that be detected 11 in an examination of Adam in the way that Dr Taylor is 12 describing?

13 A. It is something that would have gradually dawned on him,14 crept up on him.

15 No, sorry, I would like to put it a slightly different Ο. way because that has you sort of standing in the shoes 16 17 of Dr Taylor. The sort of examination that Dr Taylor is here describing, he said: I would look at his vital 18 signs, look at his face, look at his pupils looking for 19 signs of recovery. If that is the sort of examination 20 21 that you are conducting, would you be able to detect 22 whether Adam had indeed had some sort of loss of his 23 muscle tone at that stage?

24 A. At that stage?

25 Q. Yes.

1 Δ Can I elaborate on this? Closure of an abdominal wound 2 isn't an instant process, it takes the surgeon for a wound like Adam's, I would estimate, 15 to 20 minutes 3 because there's various layers that have to be closed, 4 one of which is the muscle. The surgeon would first of 5 all satisfy himself that the operation itself was 6 7 satisfactory, that there was no ongoing bleeding from 8 anywhere, and then he would close the various layers of 9 tissue, beginning with muscle.

Once the abdominal muscle is brought together 10 securely by the surgeon, there still remains a layer of 11 fat and a layer of skin to be sutured, which takes some 12 13 time. They can be sutured without the same rigour for 14 muscle relaxation as when the muscle layer is closed. 15 So it would be appropriate for the patient to begin -or the anaesthetist to seek the return of spontaneous 16 17 ventilation as the skin layer is being closed, 18 typically, to try and time the withdrawal of muscle 19 relaxant, try and time the withdrawal of anaesthetic 20 agent such that the respiratory drive is present as the 21 final layer is being closed as the wound is being 22 cleaned by the nurses and a dressing placed over the 23 wound.

24 Q. Yes.

25 A. So there's a period of 5 or 10 minutes when the

- anaesthetist would actively seek for the patient to
 begin to breathe normally.
- 3 Q. Yes.

A. And it would be during that period of time if there was
no return of spontaneous movement, no return of
coughing, no evidence of normal increased abdominal
muscle tone that concerns would -- very serious concerns
would become very evident.

9 Q. Right. And then perhaps one final question in this
area. We've got no muscle relaxant administered after
9.30. Muscle relaxant, as you said, has an effective
duration of somewhere between 20 and 30 minutes.
13 Somewhere thereabouts. The wound closure is starting
14 somewhere about, I think, quarter to 11, something of
15 that sort?

16 A. I think I worked out at the very earliest 10.30.

17 Q. At the very earliest 10.30, so somewhere in or around 18 then. Nobody entirely knows. We know that Mr Keane has 19 himself leaving just before it happened or when it was 20 about to happen, and we know people have expressed 21 a view as to how long it would take. And so working 22 back, you try and work out when that must mean that 23 he was leaving and the muscle closure was -- and the 24 wound closure was happening, but probably somewhere between 10.30 and 10.45 perhaps on the evidence. 25

1 So if that's the case, and you realise that you've 2 administered no muscle relaxant, there's been no 3 prompts, no cues from everybody, or anybody who would be 4 in a position to assist you with that, at what stage 5 do you start to get concerned about the patient? 6 A. I would begin to get concerned from thereon.

7 Q. Where is thereon?

8 A. From the point that it had dawned on -- thought about 9 things and said, "Why is that patient not beginning to 10 cough? It's an hour plus since I've given him any 11 neuromuscular block. There's no muscle tone." Usually 12 I'm being asked by the surgeon or there's consternation 13 about the difficulty in bringing the wound together at 14 this point in time. Why am I not -- what's happening?

15 If one looks at this more generally, the commonest 16 reason for that happening at that point in time is 17 there's still a residual effect of neuromuscular 18 blockade which can be examined for and tested in the 19 operating theatre.

20 Q. And how do you do that?

A. By a readily available device where an electrical
impulse is applied to the skin overlying a peripheral
motor nerve, commonly the ulnar nerve at the wrist,
which will make the muscles of the hand contract. It
should be available in every operating theatre up and

- 1 down the country.
- 2 Q. In 1995?
- 3 A. Yes.
- 4 Q. Okay.
- 5 A. And it provides a very quick assessment of the presence6 or absence of a neuromuscular blockade.
- 7 Q. Is that something, if you were that situation, you feel8 you would have done?

9 Α. That would be the first thing I would do, check for 10 residual drug effect. It always remains the possibility that one might have inadvertently given more than one 11 12 thought, made a simple mistake in the dose given. 13 There's always a possibility that if you had a trainee 14 anaesthetist with you, they've given some -- they've not 15 recorded in the chart and then walked out to do something else or been distracted. And there's 16 17 a natural variation among the population as to the duration of effect for the administration of any drug, 18 19 including neuromuscular blockade such as atracurium. 20 Q. Although this was apparently given, leaving aside the 21 one-hour interval, at fairly regular intervals. But in 22 any event, you say that's the first thing you would have 23 done and you would have -- I think your evidence was 24 you'd have been prompted to do that round about the time of wound closure? 25

- 1 Α. Yes.
- 2 Before? Ο.
- A. At or around. I don't think I'd be looking -- I don't 3 think that the issue would have been prominent in my 4 thoughts until round about that point. 5
- б 0. And --
- 7 MS WOODS: I wonder if we could just clarify at what point 8 in wound closure? Because Dr Haynes has described it 9 being a staged process.
- 10 MS ANYADIKE-DANES: Yes, thank you very much.

You've described that as a process that might take 11 12 10 to 15 minute, I think you said.

13 THE CHAIRMAN: I think the wound closure would take 15 to 20 minutes. It was the final skin layer. The closure of 14 15 the final skin layer would take 5 to 10 minutes of that 15 to 20 minutes; is that right? Approximately? 16 17 A. It depends on the kind of sutures used by the surgeon, 18 particularly of the skin. If one says that closure of a wound of the size that Adam had would take 20 minutes 19 20 overall, then no more than 10 minutes would be taken up 21 with the skin there.

22 THE CHAIRMAN: Okay.

23 MS ANYADIKE-DANES: And --

- 24 MR MILLAR: Sir, I think the evidence has been that the 25
 - anastomoses are complete at about 10.30. I appreciate

there's uncertainty, but that seems to be the working 1 2 estimate at present. I think then the evidence has been 3 that after you complete the anastomoses, you don't move 4 direct to wound closure. There's the re-implantation of the ureters after that, which takes a period of time. 5 б The anastomosis is 10.30, this further surgical 7 procedure, which takes a period of time, and I think 8 it's after that one moved to wound closure. I'm not 9 sure the assumption one moves to wound closure at, say, 10 10.45 quite fits with the evidence we've had so far, for what it's worth. 11

12 MS ANYADIKE-DANES: Thank you very much. That is helpful. 13 In all of this we're trying to time by benchmarking 14 things to other events exactly what happened where we 15 don't have accurate times. But if that's correct, that you have the anastomoses, which is recorded at or about 16 17 10.30, then there's the ureter implant that has to 18 happen and that takes a period of time, and then you've 19 got a --

20 THE CHAIRMAN: Do you have any idea what period of time that 21 might take? Again --

A. It would depend on the surgeon and depend whether it was
a straightforward procedure. But I'd imagine, no -I'll rephrase that. It is my understanding that
a straightforward implantation of the ureter into

the bladder would take about 15 minutes. No more than 1 2 that. MS ANYADIKE-DANES: That puts us to, assuming that it was 3 straightforward, quarter to 11. Then if you're saying 4 that the total wound closure might be 20 minutes, 5 б I think you said? 7 MS WOODS: Mr Brown's evidence is that it would take about 8 15 minutes. That was his best guess. 9 THE CHAIRMAN: And this witness has said 15 to 20, maximum 10 20. So we're in the same area. MR MILLAR: Sir, just since we're teasing this out, there's 11 12 the suprapubic catheter to go in as well. 13 MS ANYADIKE-DANES: Quite right. So you have re-implanted 14 the ureters, you have to insert the suprapubic catheter, 15 we'll hear from the surgeon, I'm sure, how long they think it would have taken them to do that, but 16 17 do you have any idea yourself as to how long that's 18 likely to take. A suprapubic catheter? 19 Α. 20 Ο. Yes. A minute, two minutes. A brief procedure, very brief. 21 Α. 22 Slightly after 11 o'clock. Then we've got anywhere Q. 23 between 15 and 20 minutes for wound closure. Quarter 24 past, 20 past 11. Atracurium, last administered at 9.30. And then if you've got 9.30 on that side, 25

1		somewhere the start of the wound closure maybe
2		11 o'clock, taking up to quarter past, 20 past. Those
3		parameters.
4		When do you think you would have started to be
5		a little concerned about the lack of any prompts in
6		terms of muscle relaxant requirements in that space of
7		time?
8	A.	Let me think through times again. Say the clamps came
9		off
10	Q.	9.30 was the last administration of it?
11	A.	The kidney was perfused at 10.30. Say the
12	THE	CHAIRMAN: The implantation of the ureters are about 15
13		minutes after anastomosis.
14	A.	That would take us to quarter to 11, maybe a little bit
15		earlier.
16	THE	CHAIRMAN: Suprapubic catheter, 1 on 2 minutes.
17	A.	Say that takes us to ten to 11.
18	THE	CHAIRMAN: Then wound closure.
19	A.	The requirement for muscle relaxation would be at the
20		beginning of wound closure, which takes us to just
21		before 11 o'clock. As far as we can ascertain by
22	MS 2	ANYADIKE-DANES: So normally speaking, you'd be wanting
23		to make sure that the muscles were sufficiently relaxed
24		at 11 o'clock for wound closure?
25	A.	Yes. And it has to be borne in mind that there is

1 a conflicting demand that you are near the end of the 2 operation and you will want that patient to breathe in the near future. 3 4 Ο. Yes. Yet you still need to get this part of the procedure 5 Α. б over. 7 It's a slightly different question I have asked. Ο. So 8 you've got one and a half hours there; is that right? 9 Α. Yes. Q. What I am trying to find out from you is, you have 10 a drug which has a life, if I can put it that way, of 20 11 12 to 30 minutes or so. It has, for reasons which you 13 don't know, been administered roughly every half hour. Nothing after 9.30. And you've got an hour and a half 14 15 gap with no prompts or cues, assuming --MR UBEROI: It obviously lasts until 10 o'clock. 16 17 MS ANYADIKE-DANES: Yes. So after 10 o'clock, from between 18 10 o'clock to 11, no prompts or cues in relation to the 19 need for muscle relaxant. At what stage do you become concerned and want to see what may or may not be 20 21 happening? That's the point I'm making. 22 My appraisal of this is that concerns would first begin Α. 23 to pass through my head as the wound layers were 24 beginning to be brought together, which we've just agreed is shortly before 11 o'clock --25

1 Q. Yes.

2	A.	as best we can guess. Unlikely to be before quarter
3		to 11, unlikely to be much after 11.
4	Q.	You, I think, have said that with that concern would be
5		a need to determine what was happening, and that you've
6		indicated what your first examination would involve to
7		see what was happening, which was the stimulus of the
8		nerve, the ulnar?
9	A.	Yes.
10	Q.	Thank you. If you remained concerned, what do you do
11		about that? Is there any discussion you have or do you
12		just sort of beaver away by yourself, worried about
13		what's going on?
14	A.	The first thing to do, as you say, is make sure there's
15		no residual neuromuscular block. Second is to withdraw
16		the anaesthetic agent, by which time one would have had
17		a chance to assimilate some thoughts.
18	Q.	Sorry, before you assimilate your thoughts, can I just
19		ask you, if you're going to take the step of withdrawing
20		any anaesthetic agent, do you advise the surgeon that
21		you're going to do that?
22	A.	I wouldn't do it
23	Q.	Sorry?
24	A.	If the concern was within my mind at that point, I would
25		want to clarify those concerns to some degree before

1 I discussed it.

2 Q. Right.

A. As the responsible person. Because otherwise, you end
up with conjecture and comment that just may confuse the
issue further. So I'd want to crystallise my thoughts
as rapidly as possible.

7 Q. Okay. So --

A. And at the point of concern when I would have realised
that there actually was something that wasn't just
a simple mistake in drug administration or something
that had a readily identifiable cause, you'd have to
discuss it with the senior surgeon.

13 Q. Assuming they were still there?

14 A. You took the words out of my mouth.

Q. So is it possible that the tests that you would apply to satisfy yourself before -- so as not to embark upon conjecture with the surgeons, may take sufficient time that the surgeon would have completed the closure of the

19 wound and left?

20 A. If you're talking about Mr Keane or Mr Brown?

21 Q. Whoever was closing the wound.

22 A. I think Mr Brown was left to close the wound.

23 Q. Yes.

A. I think that looking at the timing of the various eventsthat we're discussing here, I think it quite likely that

Mr Keane may no longer have been present at the time.
 I'm saying I, you could say Dr Taylor was beginning to
 be concerned.

4 Q. And for Mr Brown?

A. It depends on what relationship, what discussion was
being held between Dr Taylor and Dr Brown, because the
responsibility for the case, for the operation,
certainly began with Dr Taylor and Mr Keane and,
normally, responsibility for the patient afterwards
would remain with the surgeon. So the surgeon should
know if there's a major problem.

12 Q. Yes.

13 THE CHAIRMAN: Sorry, doctor, you said before you would 14 raise any concerns with the surgeon you would withdraw 15 the anaesthetic agent to avoid unhelpful or unnecessary 16 conjecture.

17 A. Correct.

THE CHAIRMAN: And you've also said that for a three or 18 19 four-hour operation, withdrawing the general anaesthetic 20 or the wearing off of the general anaesthetic effect, 21 that takes about 15 to 20 minutes. So if you start 22 to -- and this is difficult and hypothetical, but if you 23 had started to do that at about 11 o'clock when your 24 concerns began to appear, then you wouldn't have spoken to the surgeon for, am I right, 15 to 20 minutes until 25

1		the anaesthetic had worn off and you would then have
2		known if your concerns were justified or not?
3	A.	That's a logical conclusion.
4	THE	CHAIRMAN: Is there a but coming?
5	A.	Yes, there is a but. The but is the discussions you
6		would have would depend on your relationship,
7		interaction under normal circumstances between yourself
8		and the surgeon. If it is someone with whom you have
9		worked for many years, with whom you have much in
10		common, who you are comfortable about sharing any
11		discomfiture with, then it's likely, I think, you'd
12		broach the subject a little bit sooner. If it's someone
13		with whom you don't work regularly, with whom you're
14		uncertain of the verbal dynamic, if you like, between
15		them, then you would hesitate a little bit perhaps
16		before raising the subject.
17	THE	CHAIRMAN: Since Mr Keane and Dr Taylor didn't work in
18		the same hospital, there does not appear to have been
19		any relationship between them and, in any event, it
20		appears at least possible that Mr Keane had left by
21		then, because Mr Brown appears to have closed the wound,
22		though he doesn't recall it. Mr Brown and Dr Taylor did
23		work in the same hospital. I don't think we have
24		a clear picture of how frequently they worked together
25		or how much they knew each other, but even to the extent

1		that they had worked together and did know each other,
2		which they must surely have done if one was a paediatric
3		surgeon and the other one was a paediatric anaesthetist,
4		then you would have expected a conversation,
5		a discussion, to develop as the anaesthesia was
6		lightened or was removed.
7	A.	Yes. I think that is put like that, I agree with
8		everything you say.
9	THE	CHAIRMAN: There's a degree of speculation in what I'm
10		saying
11	A.	Yes.
12	THE	CHAIRMAN: but this does put us some time after
13		11 o'clock.
14	Α.	Yes.
15	THE	CHAIRMAN: Right. Thank you.
16	MS V	NOODS: Sir, the words you've used are "you would have
17		expected a conversation a discussion to develop".
18		I wonder whether I'm just postulating this it's
19		better to express it in the information must come from
20		Dr Taylor, a discussion can't develop unless Dr Taylor
21		actually raises it with whoever is present at the time.
22	THE	CHAIRMAN: Sorry, yes. I take your point. I think the
23		witness is saying that this would be something which
24		would be started by Dr Taylor. Your initial point was
25		that you wouldn't immediately raise your concerns until

you began to see whether your concerns were warranted, but I think, as you coloured that a few minutes later, the extent to which you would do that or whether you would do that would depend on what your relationship was with the surgeon, how well you knew him and --A. How comfortable you felt broaching a potentially difficult subject.

8 THE CHAIRMAN: But I think the intervention is to the effect 9 that the starting point for this would come from the 10 anaesthetist.

11 A. Yes.

12 THE CHAIRMAN: Right. Would that be even if the lack of 13 response from Adam was also -- would it not also have 14 been apparent from what you've said to the surgeon? 15 I mean, the prompts you were talking about aren't necessarily only for the anaesthetist to pick up. 16 17 A. No, but the surgeon would be concentrating typically on the task in hand and it would -- in terms of hierarchy 18 19 of things that he was concentrating on, it would not be at the top. 20

21 THE CHAIRMAN: Right.

22 MS ANYADIKE-DANES: Sorry, if I just pick up --

23 MR MILLAR: Mr Chairman, the other thing the witness could 24 consider at this point is obviously the surgeon has no 25 way of knowing when or whether the muscle relaxants have

1 been discontinued.

2	THE	CHAIRMAN: Let's just confirm that. Would the surgeon
3		know that? He would assume it had been administered?
4	A.	He would assume that it had been given appropriately and
5		the operation had been done and that he wouldn't want to
6		know any details of it.
7	MS A	ANYADIKE-DANES: I think when you were giving your
8		evidence, though, you said there is quite often
9		a tension between the surgeons who want muscle relaxant
10		at the time when they're closing and the anaesthetist
11		who actually wants to administer less or keep it as low
12		as possible because they want the patient to breathe
13		spontaneously once there is closure in the wound.
14		In that case then is not the surgeon concerned about the
15		fact that they are embarking on closing the wound or are
16		coming to the end of closing the wound and there's been
17		nothing at all?
18	A.	I think it would not cross the majority of surgeons'
19		minds. Surgeons really as a group really do at this
20		point tend to concentrate on the task in hand and make
21		the assumption and very infrequently raise any or
22		initiate any discussion about
23	Q.	So they're only concerned if actually they're detecting
24		some sort of movement, that's what they're concerned
25		about?

A. They would be concerned if their job was being made
 difficult because of inadequate anaesthesia or muscle
 relaxation, and they would expect to know if there was
 a significant problem, maybe not instantly, but shortly
 afterwards.

There were two other things I wanted to ask you. 6 Ο. 7 Firstly, maybe I can address something that the chairman 8 raised, which is how often that Dr Taylor and Mr Brown 9 might have worked together. Well, in relation to Adam 10 himself, the schedule of Adam's surgical procedures at 300-060-107 discloses that they worked on two occasions 11 12 simply in relation to Adam, it's the third procedure if 13 you see the line there, which is on 20 December 1991. 14 That was a transuretero urostomy. And then on item 8, 15 which is 25 February 1992, and the fourth one, sorry, also, the laparotomy on 24 December 1991. 16

17 So in relation to Adam, they had worked on three previous occasions. And then because we had called for 18 the theatre log in relation to November 1995 -- and you 19 can see that at 301-124-686. This is just obviously 20 21 a snapshot of time in November. One can see on the right-hand side, which is the date, as it happens, 22 23 14 November 1995, we have them working there together 24 in that theatre for four procedures. You can see their names across, Brown and Taylor. 25

1 THE CHAIRMAN: I think the point generally is that

2 a paediatric surgeon and a paediatric anaesthetist who
3 are working in the same hospital and have been there for
4 a number of years will have some relationship with each
5 other.

They will have undoubtedly worked together regularly. б Α. 7 I don't know the actual size of the hospital in terms of 8 numbers of consultants, but it would be relatively 9 small. It would be a relatively small number of 10 surgeons, a relatively small number of anaesthetists. MS ANYADIKE-DANES: Can I ask you this question. I think 11 12 what you had said is depending on your relationship with 13 the surgeon, you may or may not have wanted to entirely 14 exclude the possibility of the remnant of anaesthesia 15 affecting matters. If you're more comfortable with the 16 surgeon, then you don't mind raising your concerns 17 earlier. If you're less comfortable, perhaps, you 18 indicated you wanted to be more certain. But what I 19 wanted to ask --

20 MS WOODS: I just want to be absolutely clear that what 21 we're talking about here is Dr Haynes' practice. We 22 absolutely cannot begin to think what may or may not be 23 going through Dr Taylor's head.

24 MS ANYADIKE-DANES: No, I hoped that I had prefaced all 25 these questions with: this is your view of what you

1 would have done in that situation. Whether or not
2 Dr Taylor and Mr Brown had worked together is another
3 issue that the chairman has expressed a view on. But
4 all these questions that I'm posing to you is what you
5 would have done in those circumstances.

And the particular question that I was going to ask 6 7 you then is: as you are lightening or at least trying to 8 reverse the residual anaesthesia to see whether that is 9 providing enough anaesthetic to depress any movement, if 10 I can put it that way, as you are doing that, are you over that period of 15 minutes, or however long it takes 11 to you completely redress that, are you looking to see 12 13 whether there are prompts and signs or do you simply 14 start the process and see what happens at the end of 15 15 minutes?

16 A. No, you look as you go along.

17 Q. So as you're getting closer to the complete withdrawal, 18 are you getting more concerned that this is something 19 quite serious or can you not start to form a view --The longer it takes, the more concerned I would get and 20 Α. 21 I imagine my colleagues wherever would get. You may not have to wait for the entire 15 minutes to be 22 Q. 23 concerned about it?

A. No. If I can put it into context, this kind ofsituation does arise from time to time and this is the

first time I've been involved in a case where there's 1 2 not been a satisfactory resolution in terms of patient 3 outcome. Q. Thank you. Mr Chairman, I was going to move on to the 4 last area, which is the diagnosis of brainstem death and 5 б the time of brainstem death. I wonder if, given that, 7 it might be a moment to --THE CHAIRMAN: Okay. 8 9 MS ANYADIKE-DANES: I'm happy to continue. THE CHAIRMAN: Can we start again at 2.05. It seems, 10 Dr Haynes, that it might not take very much longer for 11 12 your evidence to finish. If there are any questions 13 they can be fed in over lunch. I'm keen to get started with Mr Rigg and Mr Forsythe. 14 15 (1.15 pm) (The Short Adjournment) 16 17 (2.05 pm) 18 THE CHAIRMAN: I now understand the apprehensive look on your face before lunch when I said you'd be finished 19 this afternoon. I think you're being collected at 3; is 20 21 that correct? 22 MS ANYADIKE-DANES: Two very quick questions, but I will put 23 them after we've dealt with the brainstem death because 24 that issue really needs to be addressed. The diagnosis of brainstem death first arose when matters were being 25

1 discussed amongst the experts on 9 March. The meeting 2 in Newcastle. Do you recall that? 3 Α. Yes. 4 In fact, there's a transcript of it, which starts at ο. 307-008-267. I think it's you who raised it, is it not, 5 б Dr Haynes, that you might raise an issue and say that 7 he was still hyponatraemic at the point he was declared 8 brainstem dead? Is that correct? 9 A. That's correct. Q. Then over the page, in fact given the time constraints, 10 this is an issue that is discussed from that first 11 12 reference I gave you up until the reference of 13 307-008-277. So I'm not going to take you all the way 14 through it, you were there, there's a transcript of it 15 for those who want to see it, but that was the first 16 place where it arose. 17 I wonder if you can help us with the concern that 18 you had. 19 A. Yes. Could I ask you to put up -- there's a flowchart 20 from one of the references I gave you. I think it's 21 page 17. Page 17 of it, yes. It would be 306-035-0021. 22 Q. 23 Α. Thank you. This is -- would it help if I very briefly 24 outlined how brainstem death is diagnosed in the UK? Yes. Can I just be clear that we are talking about 25 Ο.

1 1995, which is the relevant time.

2 A. Yes. There's no difference in 1995 and in current times3 between the legislation.

4 Q. Yes. This code is in fact dated March 1998, but I think
5 you're saying that it would have been applicable in
6 1995?

7 A. Completely, yes.

8 Q. Thank you.

9 A. It also has to be remembered that how brainstem death
10 diagnosis is made varies between countries, and in the
11 United States it can vary from state to state. I will
12 try and be as concise as I can in summing it up.

13 The brainstem is the area at the back of the brain 14 just above the hole in the skull through which the 15 spinal cord passes. The brainstem is essential -- or ongoing function of the brainstem is essential to life 16 17 as we know it. It contains sensors which govern the 18 respiratory drive, which govern the neural output, which 19 maintains blood pressure and the tone of smooth muscle 20 in the vessel walls. It also contains the nerve bodies 21 of several nerves which supply areas both of the head and of a nerve called the vagus nerve, which supplies 22 23 the autonomic nervous system and the airway.

24 So if there is no function of the brainstem and this 25 was -- references to this are quoted within this code of

conduct. If a patient or an individual can be certified
 as brainstem dead, that individual will go on to die as
 other people die by cessation of heartbeat fairly
 shortly afterwards, over a period of days.

5 So the brain -- and also the brainstem contains 6 nerve fibres containing all signalling information which 7 goes from the brain to the body and vice versa, sensor 8 information from the body to the brain. So if the 9 brainstem isn't functioning on a permanent basis, if 10 it is dead, then life as one knows it will not be able 11 to continue.

12 And the brainstem is an area which can be damaged by 13 other pathology within the head. Typically a head 14 injury involving a bleed, or leading to tumour, or any 15 one of a wide variety of insults, and it's damaged usually by a process called -- which is abbreviated to 16 17 coning, by which the pressure within the skull increases 18 and brain tissue is squeezed out through the foramen 19 magnum, this hole through which the brain and spinal cord pass. 20

Q. But what was your concern in relation to Adam's case?
A. Right. If you look at this flowchart, please, this is
a very concise summary of what is required in this
country to diagnose brainstem death. First of all, the
patient has to be comatose. In Adam's case, yes,
he was. And there has to be clinical evidence of the 1 2 cause of coma, possibly supported by imaging such as a CT scan, which Adam had. 3 And we know that Adam had cerebral oedema. 4 And it is my belief, and many others' belief, that the 5 б cerebral oedema was caused by hyponatraemia, a low 7 concentration of sodium in the blood. So I feel happy to move on to the third line of 8 9 this, where we look at exclusion of hypothermia, exclusion of intoxication, sedative drugs, neuromuscular 10 blocking drugs, all those I'm happy were excluded. 11 And then the next sentence says: 12 13 "Severe electrolyte, acid base or endocrine 14 abnormalities as causative." 15 And it's the fact that -- well, perhaps it would help if I went through the rest of this chart before 16 17 coming back to it. The text goes that the clinicians have to be 18 19 convinced that all these causes of coma are excluded and 20 they can then go on to perform the bedside examination, 21 which allows brainstem death to be diagnosed, details of which I don't think need to be elaborated on at this 22 23 point in time.

Then the diagnosis of brainstem death is reached if all these criteria are fulfilled. And then ventilation

can be withdrawn, the patient is declared dead. But the
 patient is not declared dead until two doctor on two
 separate occasions are convinced that everything meets
 these requirements.

5 Now, I have to preface this by saying that having 6 seen what happened to Adam and looking at the time 7 course of events, and having looked in depth at all the 8 events which have been discussed and will be 9 subsequently discussed at this inquiry, I have no doubt 10 in my own mind that Adam was brainstem dead. Absolutely 11 none whatsoever.

But if we return to the code of conduct or the requirements, the third line down, I have anxieties raised if we could outline where it says "severe electrolyte, et cetera, abnormalities".

Adam died because of a severe electrolyte Adam died because of a severe electrolyte abnormality. Now, in my view, and I am confident to say in the view of everybody else, that doesn't mean to say that brainstem death couldn't have and shouldn't have been diagnosed.

21 If we are now able -- if we could perhaps show 22 a chart that we showed yesterday where it gives the 23 flowchart of laboratory investigations performed on Adam 24 in the intensive care unit.

25 Whilst that's being outlined, we could -- I can

perhaps come back to it. Adam, as we know, returned from the operating theatre to the intensive care unit with a serum sodium level at, if I remember correctly, 119.

5 Q. Yes.

A. There were several more assays of that made. I think
there was a total of four. And the -- I don't have this
in front of me. I'm sure it'll be found for us shortly.
Shortly before the second set of brainstem death testing
was done, his serum sodium was 125.

11 Q. Sorry, I beg your pardon. Would you like to see that 12 flowchart up now as you're speaking through it?

13 A. I'm sure it'd help everyone else.

14 Q. 057-007-008. That's the one you mean, I think.

A. Yes. We can see on the left that there's the date and
time of the sample taken and in the middle it says,
"Blood chemistry". And the third one along is sodium,
NA.

19 So we see 134 preoperatively, 119 when he came back 20 to the intensive care unit. And the last two are 121 21 and 125. So he was still hyponatraemic either at or 22 shortly before the time the second set of brain death 23 tests were done.

24 Q. With a normal range being 135 to 145?

25 A. That's correct, yes. And I feel I am obliged to point

1		out that I have some discomfort that although I cannot
2		for one second believe that he wasn't actually brainstem
3		dead at the point both sets of tests were done, that
4		more strenuous efforts to return his serum sodium over
5		the intervening hours to a more normal value hadn't been
б		made. I'm also a little bit concerned because the
7		general principle of care of a patient in a coma is that
8		until he or she is declared brainstem dead, there is
9		that patient should be treated as if they have
10		a recoverable condition.
11	Q.	What would that have meant?
12	Α.	That would have included taking active steps to attempt
13		to normalise over a period of hours the concentration of
14		sodium in his blood.
15	Q.	Yes. Now, I think you said that you were all agreed.
16		Did you mean by that you being all the experts in
17		Newcastle?
18	A.	Yes.
19	Q.	Although I'm not going to go through it all, I wonder if
20		I might give some references that might help. I don't
21		have the inquiry references, but if you have the first
22		reference for the first page, if you go to the next
23		page, which is 106 in mine, if you start at line 6
24		you've got Professor Kirkham saying she'd have wanted
25		the saline to be normal, and she goes on to talk about

1 that.

2 Then if you go to line 19 of that page, you deal with blown pupils at that stage. Then if you go to the 3 following page after that at line 18, there's 4 a reference to Professor Kirkham saying you would want 5 to have a normal metabolic situation. 6 7 Over the page again at line 9 you have got Professor Gross' views on what they would do in Germany 8 9 about that, including an EEG, and there is some discussion with the experts as to whether an EEG should 10 in fact have been performed to ensure that there is no 11 electrical activity in the brain. And I think all of 12 you join in on that. 13 14 Then if you go to page 110 on my pages, and I can 15 subsequently give you the inquiry reference, line 16, you have Dr Coulthard, who also expresses a doubt about 16 17 the situation and that: "I would have questioned the decision to formally 18 carry out brainstem death tests where there is still 19 a very low sodium concentration." 20 21 I think probably there's one more reference at page 111 at line 14 on carrying out an EEG of 12 and 22 23 then perhaps another the following day. 24 So in terms of what the other experts agreeing with you, is that the sort of thing you're talking about? 25

1 A. Yes.

2	Q.	Thank you. Can you just very briefly, because I'm
3		conscious of the time, explain why it is in the protocol
4		or, so far as you're concerned, important to exclude
5		these electrolyte imbalances, if I can put it that way,
6		or to rectify them?

7 Α. Brainstem death is a diagnosis made when a patient is 8 comatose, who's on a ventilator, and it is important to 9 exclude any reversible causes of that coma. The first 10 premise is to be that there has to be an underlying 11 demonstrated diagnosis, which in Adam's case there most 12 certainly was. There has to be the knowledge, and the 13 wording is no stronger than that, there has to be 14 a certainty that there is no residual effect of any 15 neuromuscular or sedative drugs or other intoxicating agents, which in Adam's case, none were present. Then 16 17 there has to be the exclusion of metabolic and biochemical causes of coma. And that exclusion has to 18 be made before doctors making the test can go on and do 19 20 the test.

Q. Okay. Can I just pull up, while you're speaking there,
the results on the brainstem death form for Adam.
058-004-009. Is that a form with which you would have
been familiar?

25 A. I would have been familiar with the form that was used

1 in the hospital where I worked.

2 Q. Yes.

3	A.	This is a form that is clearly designed by the hospital
4		itself and it serves very much as a prompt as well as
5		a formal record of the date and timing and identity of
б		people doing the test.
7	Q.	It's the prompting point that I want to take you to.
8		These things that you are saying it's imperative are
9		excluded, although you don't actually think it made any
10		difference in this case, but in terms of the procedure,
11		that are excluded.
12		If we look at F:
13		"Could the patient's condition be due to a metabolic
14		endocrine disorder?"
15		Is that what you're talking about or not?
16	A.	Yes, that's what I'm talking about. It's an issue which
17		I have thought long and hard about, and even the fact
18		that raising it will be distressing in some circles to
19		talk about. But I feel that we cannot get away from the
20		fact that more strenuous efforts were not made to
21		normalise the concentration of sodium in Adam's blood
22		following his admission to the intensive care unit up to
23		the point in time when brainstem death testing occurred.
24		I think it has to be put into context that when
25		a tragedy like this occurs to anyone, under any

circumstances, it's not always easy and straightforward 1 2 to follow the rules exactly as they're written, which is why the guidelines are written with the wording that has 3 4 been chosen. But I would have felt much happier had -at least between the first tests and the second tests, 5 б had there at least been a visible effort to try and 7 increase the serum sodium concentration in Adam's blood. THE CHAIRMAN: Doctor, can I ask you, just to make sure 8 9 I understand the significance of what you're saying. 10 This is in the context that you've emphasised that neither you nor any of the other experts actually doubt 11 12 for a moment that Adam was brainstem dead? 13 That's correct. Α. THE CHAIRMAN: So is this being raised as an issue which is 14 15 of general importance before anybody is stated to be brainstem dead that these procedures are followed, or is 16 17 there a particular significance in Adam's case? 18 Both, in fact. It's a general --Α. 19 THE CHAIRMAN: Okay, I understand the general point. What 20 is the particular significance of it in Adam --21 Α. The particular significance of it in Adam's case, 22 I feel, is that if one goes right the way back to what 23 the insult to Adam's brain was, it was a low sodium 24 concentration. 25 THE CHAIRMAN: Right.

A. And if one follows it through, then there's -- I'm possibly from a practical point of view more concerned that there weren't more vigorous attempts to normalise it from the time he was admitted to the intensive care unit before formal testing of brainstem function was carried out. Because during that time he was still a patient who wasn't dead.

8 THE CHAIRMAN: But I understand you to be saying that you 9 don't think that these efforts would have had any 10 successful outcome, or can you not say that? 11 A. No, I can say with -- I hesitate to use the word 12 "certainty", but as close as one can be that the outcome 13 was inevitable.

14 THE CHAIRMAN: Okay.

MS ANYADIKE-DANES: That was just where I was going to try and bring you to, which is precisely when you thought that moment was. There's been a number of different periods for it.

19 I think you suggest, in your report of 204-009-364, 20 9.30. And then you say or that brainstem dead occurred 21 at some stage during the transplant operation, and 22 that's at 204-012-380.

Dr Coulthard expresses a view in his report of
200-022-271 that Adam was probably brainstem dead by
between 7 and 10.

Professor Gross in his report of 201-015-236, he
 puts it as 9.32 or maybe before.

And Dr Squier at 206-002-008 has it as before 11.55. You have obviously seen all the experts' reports and seen their views as to the times they put it and the reasons for it. Bearing all that in mind and the evidence you've heard, what is your view now of when you think Adam's condition was irretrievable, if I can put it that way?

10 A. My view is that his condition was irretrievable at some11 point during the operation.

12 Q. I understand.

13 A. I don't think we can be any more precise than that.

14 Could I ask you to bring up another page though?

15 Q. Yes, of course.

16 A. Which is 058-035-and I think it's 141.

17 Q. Yes?

18 A. Now, I mentioned in my introductory preamble, if you
19 like, that one of the features of brainstem death was
20 the loss of ability to regulate the blood pressure and
21 muscle tone [indistinct] blood vessel walls.

22 When one observes a patient who has sustained an 23 irretrievable brain injury, for whatever reason, over 24 a period of hours, there are inevitably a sequence of 25 events which the observer sees. The first of those,

1 Adam was not able to demonstrate because he had no 2 functioning kidneys. That is the production of a large volume of dilute urine, because the endocrine stimulus 3 to retain fluid originates from a hormone called 4 antidiuretic hormone, which is governed by the 5 hypothalamus, which is within the brain. When that 6 7 function is gone, the ability to produce that hormone is 8 gone and water is shed in an uncontrolled manner from 9 the kidneys. But for that to work, you have to have a functioning kidney and Adam didn't. So that sign 10 wouldn't have been evident. 11

12 The next sign that one sometimes -- well, almost 13 invariably sees when observing a patient who has 14 sustained an irretrievable head injury or brain injury 15 is this loss of control of blood pressure. And I 16 believe that this page in the clinical notes is 17 describing when this happened.

18 If we recall the anaesthetic chart at the end of the 19 operation, Adam had a systolic blood pressure of about 20 100. If we read this, this is dated 28 November 1995, 21 1 o'clock in the morning.

22 And it says:

23 "Blood pressure dropping over past hour."24 I think it's mean arterial pressure down to 70.

25 Very pale, et cetera. But still fairly well perfused,

et cetera. And they go on to increase the amount of
 dopamine being given and to give Adam some more fluid to
 try and bring his blood pressure up.

I think this paragraph perhaps brings down slightly 4 the window when the actual final terminal event 5 occurred. And I think, although there was visibly no б 7 brainstem function observed at the end of the operation 8 in terms that Adam wasn't able to breathe, that he had 9 no brainstem reflexes or the brainstem reflexes of 10 pupilary response to light weren't present. I think one could say that beyond the 1 o'clock in the morning, the 11 12 morning after, he was definitely beyond doubt brainstem 13 dead beyond that point, and I don't think one can be -say with precision and clarity that it definitely 14 15 occurred before that point, though the irretrievable insult may have happened during the operation. Complete 16 17 loss of brainstem function, I think perhaps might not have happened until a little bit later, but that doesn't 18 19 mean to say that the situation was still reversible during the operation. 20

21 THE CHAIRMAN: Okay.

22 MS ANYADIKE-DANES: Thank you. There are two questions that 23 I've been asked to ask you and I'm conscious of your 24 time, so I will interpose them now to make sure I get 25 those in.

1 One is, how often would you, if you had been the 2 anaesthetist, have checked Adam's eyes during the course 3 of the operation, if you would have done so at all? 4 A. If it had been an uneventful operation and I had no 5 cause for concern during the course of a four-hour 6 period, I would certainly have looked at the end of the 7 operation.

8 Q. Mm-hm.

9 Α. But unless there was cause for concern, usually relating 10 to depth of anaesthesia, because one of the signs of inadequate analgesia, anaesthesia, are dilated pupils 11 12 and lacrimation, the production of tears. But unless 13 there was a reason to do it during the operation or 14 concern about something else, I wouldn't do it. But 15 I would automatically, without evening think, have a look at the end of the operation. 16

17 Q. Thank you. One other question on that -- well, not on 18 that, but to put to you and that relates to CVP, really. 19 Dr Coulthard expressed a view that the initial --20 appeared to express a view that the initial CVP 21 measurement of 17 is likely to have been reliable. 22 If we can pull it up quickly so you know what you're 23 being referred to. 204-012-381. He says: 24 "I've seen numerous children with a CVP measuring 17

25 to 20. They never appear normal. There is invariably

swelling of the head and neck, even when sitting up.
 The liver is enlarged and there is leg oedema. There is
 nothing to suggest that Adam was in this condition
 at the start of the anaesthetic."

5 That's your --

6 MR UBEROI: That is Dr Haynes' paragraph.

7 MS ANYADIKE-DANES: Yes. I'm putting to you what you have 8 previously responded to Dr Coulthard about. He says he 9 thought that that initial reading of 17 was likely to 10 have been, could have been reliable. I'm putting to you what you have said if you had a child with that CVP 11 12 value of 17-odd, this is how you have described that 13 child presenting, and I think that's part of your 14 argument for why you didn't think that the 17 figure 15 at the start was reliable. That's what I'm asking you 16 to comment on.

17 A. That's absolutely correct. My view is that if a central 18 venous pressure as measured in the neck is genuinely of 19 that order, the patient will have physical signs showing 20 venous engorgement, some oedema. They will not have 21 a normal appearance. You should be able to detect that 22 without measuring the CVP.

Q. Yes. Just so that we are clear about it, are you saying
that the physical signs of it are such that Dr Taylor
just would have seen that and that would be -- or others

would have seen it and that would be recorded somewhere?
 A. Yes.

Can I just ask, how many times you have seen a child 3 Ο. with a central venous pressure at that level? 4 5 Α. Because of the specialist aspect of my practice, I see б it fairly frequently. But it's not under normal 7 circumstances -- not under circumstances such as 8 a patient like Adam, who, whatever the variability in 9 his fluid balance was not massively fluid overloaded at the start of his operation. As we talked yesterday, 10 he may have been a little bit overloaded or a little bit 11 dry but certainly not of that magnitude. 12

13 The two circumstances, very broadly speaking, where 14 I've seen numerous children with a central venous 15 pressure like this are, one, when a child with severe advanced heart failure presents, such as a child 16 17 presenting for heart transplantation when the heart is 18 so distended and tense that that pressure is transmitted to the veins in the body. And the other is following 19 a specific kind of palliation in heart surgery when the 20 21 venous drainage of the head and neck, instead of going 22 back to the heart, is diverted to flow passively through 23 the lungs. And any difficulty in resistance to blood 24 flow passing through the lungs will cause a child after -- usually in the first couple of days or so after 25

this operation to visibly have a head which is very 1 2 puffy, eyelids swollen, the child can't see out, neck veins are engorged, and the pressure measured in the 3 veins of the neck will be in that order of. 4 Q. To conclude that then, if that was so, that is something 5 б that would have been present at the very outset. Well, 7 in any event, at 8 o'clock when the CVP was being 8 erected. I think what you're saying is that that would 9 have been an extremely striking appearance in that was the case? 10 Yes, and all the information I've been given is that 11 Α. Adam looked normal in appearance up to then. 12 One final question for you, and it arises out of what 13 Q. 14 you were saying yesterday about your experience as 15 a clinical director. If you can't answer this, so be it. But I was asked if you might try and assist with 16 17 it. That is, I think yesterday you were saying about what your role was and if you had had experienced 18 19 anything like this difficulty, you would have tried to see if you could get to the bottom of it yourself. If 20 21 you couldn't understand exactly what had happened, then you had no option but, I think you said, you'd have to 22 go to the director who ultimately would be responsible 23 24 to the board and to see exactly what steps would have to be taken. 25

The issue that arises is this, until all that is 1 2 resolved and anybody has a very clear picture of what 3 happened and so on, nonetheless you would have with you 4 clinicians who have been involved in an event of this sort, and in particular you would have an anaesthetist 5 б who at that stage you would have identified certain 7 errors or omissions in the calculations of the fluid 8 balance. 9 What is it as a clinical director that -- what is

10 the role of the clinical director when he or she is at 11 that stage?

A. Well, I think you have to -- as frequently is the case,
one has to compare 1995 with 2012.

Q. Sorry, that was my next point, just to make sure that we're talking about 1995 because we've heard an awful lot of how things are different now. But in 1995, when it was all a little nascent, I think you said.

18 A. Yes. Now it's much clearer, much more formalised, what19 would be expected --

20 Q. Yes, but can we stay with 1995.

A. -- so let's put that to one side. In 1995 the clinical
director had broad responsibility for clinical

23 governance, whatever that meant in 1995. And certainly,

24 when I began as clinical director, what the -- the

25 interpretation among all my colleagues was that when

something wasn't going right, they came to the clinical director to see if we could have a look at it, be that a fault in the systemic approach to the way the department was run or if somebody thought there was a genuine problem with one of the doctors or surgeons, "Could I have a look at it, please?"

7 The first thing -- and this happened to me on 8 several occasions. The first thing that I would arrange 9 to do would be to ask to have a private off-the-record 10 discussion with the individual who either had or was 11 perceived as having the problem.

12 Q. Mm-hm.

Usually, the person was fully cognizant of the fact that 13 Α. 14 they weren't performing to the best of their ability 15 either on that occasion or in general, and in those days if someone knew they weren't performing to the best of 16 17 their ability and if it was because they were having 18 a bit of a problem with life outside the hospital, you 19 could say, "Go away for a couple of days, and come back. 20 We'll cancel your clinics. We'll take care of that. 21 Come back when you can come back to work in a calm manner and approach things and there's nothing wrong 22 23 with the patient's knowledge or practice". 24 Can we deal with a slightly different situation? Q. The situation you're talking about is a situation like 25 Α.

1

25

Adam, where something terrible happened.

2	Q.	It's not so much that. Something terrible did happen,
3		but it's not so much that that I think the question is
4		directed towards. It's when the person who is perceived
5		to be involved in it does not accept that the
б		calculations they made or whatever it was they did
7		are not that they weren't part and parcel of what
8		happened but the result was that which their colleagues
9		might think or what the coroner might have identified
10		was the cause of death. What are you as a clinical
11		director to do in those circumstances?
12	A.	Right. Let me take you back perhaps to what I envisage
13		I would have done
14	Q.	In 1995
15	A.	Well, at the beginning of my time as a clinical
16		director, which would have been 2000/2001. The first
17		thing would be to ask to have a discussion within a very
18		short time frame with the individual where the perceived
19		problem is. If the individual said, "Look, I did
20		something wrong that day. I know I did something wrong.
21		I don't normally do that. I know I made a mistake.
22		I will never do it again. It's terrible", then the
23		situation would appear to be resolved.
24		If the individual comes into your office and sits

127

down and clearly has no perception that they've done

something which has caused misadventure, then that
 conversation at that point can't go any further.

The next thing I would do is say, "Can you come back, perhaps tomorrow, or maybe this afternoon, but within a very short time space and I will ask one of our senior colleagues to come in and join in this discussion". At that point I would minute it and take notes and records.

9 If at the end of that, there was still -- I was 10 still unhappy that the person whose practice was being challenged -- and that there was a real problem, and 11 that that person's perception of their own practice was 12 unchanged, they felt they'd done nothing wrong, they 13 14 were going to continue doing exactly the same again, at 15 that point in time you have to take the matter further with a degree of urgency. 16

17 If I say -- if I call myself a junior clinical 18 director for the first six months or year of my time 19 doing it, that would perhaps equate to whoever was in charge in 1995 in Belfast Children's, then you have no 20 21 option but to go and seek senior support in what you are doing. If something of this magnitude had happened and 22 23 there hadn't been a satisfactory local resolution of 24 that problem within a fairly short space of time, we're talking days, the medical director of the trust would be 25

hearing from me and in many ways it would be passed up 1 2 to the medical director to take further, which would make the whole thing an awful lot more formal and may 3 4 involve bringing in of outside agencies to look at 5 events. б THE CHAIRMAN: There's no mystery about that. 7 Α. It's common sense. 8 THE CHAIRMAN: [Inaudible: no microphone]. You can't allow 9 that person to continue until you're reassured that this 10 will not happen again. A. Absolutely. 11 12 THE CHAIRMAN: And to do that, you don't have to wait for 13 the inquest finding? 14 A. No. 15 THE CHAIRMAN: Which comes the following spring. You have to act immediately? 16 17 A. It should be done in-house or within the home-base organisation within a short period of time. 18 THE CHAIRMAN: You're talking about a few days, aren't you? 19 20 Because within that time the same doctor will be 21 operating on more patients? A. Yes. 22 23 THE CHAIRMAN: Thank you. 24 MS ANYADIKE-DANES: Thank you very much, sir. I don't have 25 any further questions unless my colleagues do.

THE CHAIRMAN: Mr Hunter on behalf of Adam's family. 1 2 Ouestions from MR HUNTER 3 MR HUNTER: Dr Haynes, you have said in one of your reports, and I can give the reference, it's 204-004-170, that: 4 "It is customary to keep his head [that is the 5 patient] visible during an anaesthetic whenever possible 6 7 and to examine it including looking at the pupils at 8 intervals during a long operation." 9 Can I ask you when you say it's customary, does that mean it is accepted practice or standard practice? 10 It is standard practice that whenever possible you keep 11 Α. 12 an area of the patient available for examination and 13 inspection. It's something that was instilled, is 14 instilled from day 1 of your anaesthetic training that, 15 if you can, you want to be able to have a -- see as much of the patient as possible. 16 17 Q. And when you say that that includes looking at the 18 pupils at intervals, how often would you check the 19 pupils, at what intervals? A. I think I've answered that question earlier, but I'm 20 21 more than happy to answer it again. 22 THE CHAIRMAN: Unless there was a cause for concern, you 23 would not normally look at the pupils until the end of 24 the operation? In the normal course of events, in a long operation, 25 Α.

there are inevitably times when you might wonder if the 1 2 depth of anaesthesia is adequate or not, and you may wish to look. So it's hard to answer with absolute 3 4 precision, other than to say we'd certainly look at the pupils at the end and may well have reason to look at 5 б intervals, but how often those intervals are depends on 7 the pattern of events as they unfold. But it's 8 certainly normal practice if you can to keep an area 9 available for visualisation around the patient's head 10 and neck if they have an operation in the lower half of the body. 11 12 MR HUNTER: Thank you very much. 13 Ouestions from THE CHAIRMAN 14 THE CHAIRMAN: Thank you. 15 No more questions? Can I just raise one other issue with you. We fell behind a little in our progress and 16 17 we haven't heard evidence yet from Dr Montague, who 18 you will recall was the registrar who at the start of the operation was assisting Dr Taylor. 19 20 A. Mm-hm. 21 THE CHAIRMAN: And Dr Taylor's initial position in his 22 written statement was that Dr Montague had agreed the 23 fluid input and this was a team effort, in essence, 24 he was saying. Right? Now, Dr Taylor has now accepted

131

that these were his mistakes and his responsibility.

What is the extent of a registrar's input and responsibility when working with a consultant? I'm sure you can speak for days on that, but is there a short summary version you can give?

5 A. The short summary is that, by and large, the consultant 6 is responsible for the registrar's actions. If that 7 consultant thinks that that particular registrar is 8 capable of doing that particular case on his or her own 9 without any input from the consultant, then that's his 10 decision, and providing he remains available, that's 11 fine.

12 At the other end of the spectrum you have a complex 13 operation, a relatively inexperienced registrar who 14 certainly is not familiar with the particular 15 surroundings at that time and the way the hospital works, has been out of clinical practice for a while. 16 17 I would expect Dr Taylor to have taken pretty much 18 complete responsibility for everything regarding Adam 19 and would have wanted to know, even if the registrar was doing something -- he would want to check it was being 20 21 done to his satisfaction.

THE CHAIRMAN: How aware would a registrar be in a normal situation of what the consultant is doing? You have described it to me in terms of the consultant being responsible for the registrar's actions, but in this

1 case we have a consultant who, on your view was, to put it bluntly, he had made some terrible mistakes, and he 2 3 himself has accepted that he made some terrible mistakes. To what extent is it reasonable to say surely 4 Dr Montague should have or might have picked up on some 5 б of that? 7 I think it's a very valid point to which it's quite hard Α. 8 to give a concise answer. If Dr Montague had realised 9 that something was being done which was to his mind incorrect for whatever reason, then I would expect him 10 to have alerted Dr Taylor. 11 12 THE CHAIRMAN: That's why I asked you to what extent he

13 would know what Dr Taylor was doing.

14 A. I think that it is unlikely, given his sphere of
15 clinical practice, leading up to this time, that he
16 would have fully realised, appreciated the significance
17 of everything that was happening.

18 MS ANYADIKE-DANES: Sir, I wonder if I might ask a question.19 THE CHAIRMAN: Just one second.

20 What then is the value of Dr Montague's presence? 21 A. That's a question which was asked in the preparation of 22 one of my reports. The value of Dr Montague's presence 23 is he has -- one has to ask is the trainee present for 24 the trainee's benefit, the consultant's benefit, the 25 patient's benefit or all three? And depending on the

circumstances and depending on the experience of the
 trainee, that might be completely variable.

3 Trying to be as precise as possible, the answer to that question is Dr Montaque was a skilled pair of hands 4 able to carry out specific tasks to assist Dr Taylor. 5 б There would also have been periods of time when, if 7 everything was stable, it would have been entirely 8 appropriate for Dr Montague to remain in the operating 9 theatre, assuming everything was proceeding in a satisfactory manner while Dr Taylor could take a brief 10 break and vice versa. 11

12 Given that Dr Montague was inexperienced in this 13 sphere at that time, one reaches the conclusion that 14 Dr Montague's presence was very much for the benefit of 15 training Dr Montague.

16 THE CHAIRMAN: Right.

17 MS ANYADIKE-DANES: The evidence in relation to this, 18 certainly from Dr Taylor, not necessarily always 19 accepted by Dr Montague, is that prior to Adam's 20 surgery, or at least being anaesthetised, the fluid 21 management plan was discussed between Dr Taylor and 22 Dr Montague. In fact, had Dr Montague given his 23 evidence before you'd given yours, we would have had 24 that evidence of exactly what was discussed on what basis. 25

1		Leaving that aside and answering almost
2		hypothetically in the way it's been put to you, if the
3		plan had been discussed in such a way that Dr Montague,
4		who although not an experienced paediatric anaesthetist
5		was certainly a senior registrar, and in fact I think
б		within a year or so became a consultant himself, if the
7		discussion had been such as to convey to Dr Montague
8		that the plan was based on 200 ml an hour urine output
9		of Adam, is that something, given all that you said
10		yesterday, that a senior registrar should have
11		appreciated the implications of?
12	Α.	It depends to what extent he had sat down independently
13		and thought through the whole process, I think.
14	Q.	Well, are you saying that you could be told that
15		a four-year-old, 20-kilogram boy, has an output of
16		200 ml an hour and you need to sit down and work out
17		whether that is likely of, urine?
18	Α.	If it's presented as bluntly as that, the answer is you
19		would question that.
20	Q.	Thank you, but it may not be presented
21	Α.	But if it's not presented like that, then it may or may
22		not have been picked up in the appraisal of the case.
23	THE	CHAIRMAN: Dr Haynes, thank you very much indeed.
24		You're free to leave and thank you for your time.
25		(The witness withdrew)

THE CHAIRMAN: Let's take a break for 10 minutes and at 3.05 1 2 we'll come in and do Mr Forsythe and Mr Rigg, and we 3 won't go past 4.30. 4 (2.57 pm) (A short break) 5 б (3.10 pm) 7 PROFESSOR JOHN FORSYTHE and MR KEITH RIGG (called) Questions from MS ANYADIKE-DANES 8 9 MS ANYADIKE-DANES: Thank you. 10 Mr Forsythe, you, I believe -- we are going to look through your CV in a minute, but just in order to 11 12 explain how we think the evidence will run. You were 13 doing paediatric renal transplants up to 1995 and a little bit thereafter, and your input into your joint 14 15 report has been largely addressing this position as it would have been at the time of Adam's surgery. 16 17 PROFESSOR FORSYTHE: That's correct. 18 Q. Mr Rigg, you are still carrying out paediatric renal 19 transplants, and so to the extent that there becomes 20 an issue as to what are the different procedures about 21 things, you're in a position to assist with that? 22 MR RIGG: Yes. 23 Q. Were you also carrying out paediatric renal transplants 24 in 1995 or thereabouts? 25 MR RIGG: I was.

1 Q. So you can make a comparison?

2 MR RIGG: I can.

Q. Firstly, gentlemen, we have your CVs. One for you, 3 Mr Forsythe, is to be found at 306-034-001. And the one 4 for you, Mr Rigg, is to be found at 306-038-001. 5 б Do you have them there with you? 7 PROFESSOR FORSYTHE: We do, thank you. I wonder, without going through it all, because I note 8 Q. 9 that you have a considerable number of publications, 10 Mr Forsythe, I wonder if you can help and say something about your surgical background. 11 12 PROFESSOR FORSYTHE: I trained mainly in 13 Newcastle-upon-Tyne. I was appointed as a consultant 14 surgeon in the general surgery department but with 15 a particular interest in transplant surgery to Newcastle-upon-Tyne, and there I was involved in 16 17 paediatric renal transplantation. 18 I then moved to become consultant transplant surgeon 19 and general surgeon in Edinburgh and headed the unit in Edinburgh in 1995. I continued to be involved in 20 21 paediatric transplantation for the next couple of years, 22 but then the service moved from Edinburgh to Glasgow. 23 Q. Sorry, just so I am clear, when you say the service 24 moved, you mean the paediatric renal transplant service

25 moved from Edinburgh to Glasgow?

1 PROFESSOR FORSYTHE: Correct.

2	Q.	Do you know why that happened?
3	PROI	FESSOR FORSYTHE: It happened largely because of the
4		numbers involved, the fact that it was felt to be
5		sensible that the numbers were focused in one particular
б		unit, and I supported that, in fact went across to
7		Glasgow and helped with some of the first paediatric
8		transplants in Glasgow to help with that process.
9	Q.	Does that mean that the centre, when you joined it in
10		Edinburgh, simply didn't have an appropriate level of
11		numbers of paediatric renal transplants?
12	PROI	FESSOR FORSYTHE: It was true that the numbers that were
13		going to go through Edinburgh if it continued were of
14		such a size that actually it needed to be coalesced for
15		the whole of Scotland in one centre, and that's what
16		happened in Glasgow.
17	Q.	Thank you. Was there any because you have expressed
18		views in your reports as to the appropriate level of
19		if I call them the numbers the numbers of transplants
20		that really need to be done so that people can maintain
21		their skills and experience with them, and you have
22		commented on that in your report. Was there that sort
23		of discussion or, if there was, were you aware of it in
24		Edinburgh when the service was moved to Glasgow?
25	PROI	FESSOR FORSYTHE: Yes, there was discussion about numbers

and about trying to provide the best possible service
 for an extremely skilled procedure that happened
 relatively infrequently.

Thank you. Mr Rigg, I wonder if you could assist us 4 Ο. with your surgical background and qualifications. 5 б MR RIGG: I too trained in general surgery in Newcastle and 7 towards the end of my training spent a total of 8 3.5 years in renal transplantation, including both adult 9 and paediatric. Two of those years were spent while I was doing research and the other year and a half was 10 as a senior registrar. 11

By the time I left Newcastle I'd done 150 kidney 12 13 transplants and I was appointed as a consultant general 14 surgeon with a special interest in renal transplantation 15 in Nottingham in October 1992. And I would say that looking at my job plan then, about 60 per cent of my 16 17 time was spent in transplant-related activity, and the 18 other 40 per cent in general surgery. And within the 19 renal transplant that included both adult and paediatric in Nottingham, and that has continued to the present 20 21 day.

22 Q. Thank you very much indeed.

23 Now, you've produced a number of joint reports, and 24 just so we go through them so that people can locate 25 them. I think your first one was 23 June 2011. That's

1 203-002-019.

25

2 Then there's a report of 12 October 2011, which is 203-004-058. 3 A report of 19 November 2011, 203-008-105. 4 And then a report regarding comments that you made 5 in relation to document 301-121-656, that report is 6 7 dated 5 April 2012 and its reference is 203-009-111. To the extent -- well, subject to anything that you 8 9 may wish to say in your oral evidence, are you adopting 10 those reports as your view on the matters that you've been asked to express an expert view on in this case? 11 12 MR RIGG: Yes. 13 Thank you. You've given your experience and -- well, Ο. 14 it's certainly set out in your CVs and you've explained 15 some of your background and your experience paediatric renal transplants. What I propose to do is to take you 16 17 through certain aspects of the transcript of Mr Keane's evidence. 18 19 You've seen his witness statements, you've seen the 20 witness statements of the other clinicians, you've 21 looked at all the reports and you've written your 22 reports in that context. I'm not wishing to take you 23 through all that. You've said what you said and you've 24 now adopted it.

140

But what you haven't had an opportunity to do is to

1 comment on anything that the principal surgeon,

2 Mr Keane, and to some extent also Mr Brown, who was 3 assisting him, what they have said in their evidence. 4 That's what I propose to do, and to take you through 5 that and deal with certain sorts of issues.

6 So if we could start really with Mr Keane's 7 experience. In the transcript of his evidence of 8 23 April, page 6, and then from about lines 3 to 16 he 9 sets out his own experience.

I don't know if you've had an opportunity to see his CV, but we can certainly furnish that to you over the evening or in one of the breaks. Mr Keane was a urologist with an interest in transplantation, and you both have described yourselves as starting off as general surgeons with an interest in transplantation.

He said he wasn't a full-time transplanter, if I can 16 17 put it that way, and that there was no full-time transplanter in Belfast until the end of 1999, although 18 19 obviously they were carrying out paediatric renal 20 transplants. The question that arises is, from your 21 point of view, should the Belfast service, paediatric 22 renal transplant service, have had a full-time 23 transplanter? 24 MR RIGG: I think from what we said before, I'm not sure

141

25

they needed a full-time transplanter. At that time very

few surgeons were full-time transplanters. The majority 1 2 shared -- experienced both in general surgery and transplantation. There were some urologists who also 3 4 did some transplantation. I think what was important is that there were consultants who took a particular 5 б interest in transplantation, even though they also had 7 another speciality, such as urology or general surgery. 8 MR FORTUNE: Can I rise at this stage because it seems that 9 we're getting into areas that might more properly be 10 described as governance. MS ANYADIKE-DANES: I think that's fair comment. 11 12 MR FORTUNE: Also into a fairly political area, with a small 13 p. THE CHAIRMAN: I don't see it as part of my remit, just to 14 15 reassure you, Mr Fortune, to recommend to the Minister 16 for Health about how the transplant service continues in 17 Northern Ireland or whether it continues in 18 Northern Ireland. I'm assuming that that was a rather 19 unintentionally broad introduction to a specific topic. 20 MS ANYADIKE-DANES: Yes. 21 MR FORTUNE: I'm grateful for that indication. 22 MS ANYADIKE-DANES: Yes, thank you, Mr Chairman. It was. 23 Everybody will have read their reports and the 24 observations they make on those reports, and where this cascades down, if I can put it that way, is into some of 25

the difficulties it may or may not have presented for that service at that time in relation to the arrangements that were being made for Adam's own surgery. So that's really the context in which it's being raised. But I am happy, Mr Chairman, if you think it's more of a governance matter, not to really pursue it.

THE CHAIRMAN: Well, I'm not even sure it is a governance 8 9 matter, because we know in fact from the objection that 10 DLS on behalf of the Belfast Trust raised to Mr Forsythe giving evidence. We know there has already been 11 12 a report commissioned, which at least touches on the 13 future provision of paediatric renal transplants in Northern Ireland or in the island of Ireland. And if 14 15 that report is already available, I don't see it as being within the list of issues that we have set out, 16 17 which follow on from the terms of reference for me to do a report on how I see paediatric renal transplant 18 19 services continuing in Ireland or beyond in the future. 20 MS ANYADIKE-DANES: No, I certainly hope -- I wasn't 21 intending to go down that particular road. 22 THE CHAIRMAN: There's more than enough to write about 23 without that. 24 MS ANYADIKE-DANES: Yes. I'm sure.

25 The issue really is the impact of the arrangements

1 on how Adam's own surgery was carried forward and --2 well, right back from when he was first put on the transplant list up until the conduct of his own surgery. 3 4 That's really the point of it. Maybe now that we've got over the fact that the surgeons are not the surgeons 5 б in the Children's Hospital, but they are general 7 surgeons, urologists, with an interest in transplant 8 surgery and that they're based in another hospital, 9 which is the Belfast City Hospital --

10 THE CHAIRMAN: Sorry, let me go back to the original question which Mr Rigg took in a slightly different way. 11 12 You're not saying that in Northern Ireland or in the 13 Royal we needed a full-time paediatric transplanter but, as I understand your evidence, it would be helpful to 14 15 Professor Savage, who was trying to develop a service, that he had somebody such as Mr Keane who was offering 16 17 his services, who regularly did transplants and who was 18 expressing a degree of support or interest in the building up of a paediatric renal transplant service; 19 20 is that right?

21 MR RIGG: I think that's exactly right. I think it is 22 important that there is particularly one surgeon who 23 takes the lead in that. It might be helpful just --24 THE CHAIRMAN: Let's be careful. It wasn't Mr Keane who was 25 taking a lead in this. He has expressed himself in
1

general terms as being supportive of what

2 Professor Savage was doing and, therefore, being willing 3 to be someone who would contribute to the development of 4 the service. Okay?

5 MR RIGG: Okay.

6 MS ANYADIKE-DANES: I think, Mr Chairman, if I'm going to do 7 it, I will come back to this point and see how it can be 8 refined in such a way that it's of most immediate use to 9 the issues that you have to deal with in relation to 10 Adam; or help, rather.

11 Maybe I will move to the question of the protocol. 12 You have seen the protocol that was in force, it's dated 13 1990, and that's the one that was in force when Adam had 14 his surgery.

15 You'll have appreciated, I think if you've read the transcripts, that although it has been referred to as 16 17 a protocol, in fact it says in the admission protocol 18 that it has also been variously referred to as guidance, 19 an aide-memoire, really. But whatever its nomenclature, what has been clear is that the steps and issues that 20 21 are recited there are things that Dr Savage really thought ought to happen. 22

There may be reasons why in any given instance a particular thing can't happen quite like that, but that was his way of trying to record the various things

that he thinks in a typical surgery or preparation for surgery ought to happen. Is that kind of document -maybe not exactly that, but is that is kind of document something that you are familiar with from your own practice? As at that time?

б MR RIGG: At that time, and currently there is a protocol. 7 I think you're right, whether it's called protocol or 8 guidance, but I think it's there so that there is 9 a consistent approach. We know that junior staff move around very frequently and, therefore, it's important 10 that there's something written that people can follow 11 12 who come onto that unit who may not be familiar with the 13 process. That's even more important with paediatric 14 transplantation when there are never a large volume. So 15 I think it is important that there is a record there to act as a guidance for those involved. 16

17 Q. Yes. Can I ask, if one looks at this protocol and you 18 see the history on admission, and one can see how it 19 applies to the junior doctors and the nurses, even, who would be involved in preparing the child prior to the 20 21 surgery. And then if one looks down at the bottom, 22 there is an intraoperative fluid, so it does go on to 23 address matters that happen during the course of the 24 surgery.

25

Dr Savage has given -- Dr Haynes has given his

evidence as to how relevant he felt this guidance might have been to the anaesthetist. From the surgeon's point of view, how relevant is guidance of this nature? If we go over the page -- perhaps we can put the two pages side by side. 53 as well.

б

There we are.

7 MR RIGG: I think it's fair to say that this protocol in 8 common with the protocol that I've worked with over the 9 years doesn't actually cover what we as surgeons would do during the operation. It gives a guidance as to what 10 information is required in the clerking of the patient 11 and their families, so we know what needs to be recorded 12 in terms of the history and examination. It says very 13 14 clearly what investigations need to be done.

15 Often it will be different anaesthetists who are involved with the renal transplant procedure. Sometimes 16 17 it may be an anaesthetist who is very familiar and knows 18 this by heart and, therefore, doesn't need reference to 19 it. Other times it may be somebody who's doing the procedure for the first or second time who needs 20 21 a reminder. And the immunosuppression, again, there was a standard prescription written up for the child after 22 23 the operation.

24 So this is familiar. I mean, it's a short protocol, 25 but I think at that time that was entirely appropriate

1 for what was required.

2 Q. Yes.

3	MR FORTUNE: Can we be very clear with both Mr Forsythe and
4	Mr Rigg. We are talking about 1995. Mr Rigg said over
5	the years
б	MS ANYADIKE-DANES: I was just coming to that point,
7	I promise you, Mr Fortune. I was just coming to that
8	point. In fact, I was going to go directly to
9	Mr Forsythe, who is the person who is essentially his
10	practice was up to that point and a little bit over.
11	The focus of his assistance to the inquiry has been his
12	experience round about that this time. And what I was
13	first going to as Mr Forsythe is, Mr Forsythe, when
14	you were in 1995 carrying out paediatric renal
15	transplants, were you aware of any protocol that
16	affected what you did as the surgeon?
17	PROFESSOR FORSYTHE: There were protocols that affected the
18	care of the patient, but very little that actually, as
19	Keith Rigg said, affected directly what happened in
20	theatre. So there was guidance for the management of
21	the patient, but really nothing that impacted greatly on
22	what I did technically within the operating theatre.
23	Q. Understood. Would you actually have even been aware,
24	read, considered the protocol that addressed the care of
25	the patient?

PROFESSOR FORSYTHE: Yes, I would. I would have been keen 1 2 to look at that and be, if necessary, involved in 3 discussing some aspects of it. 4 Q. If we look at this protocol now, it is short, we've 5 conceded that, or you have acknowledged that. But 6 nonetheless, what are the elements of this protocol that 7 give rise to things that you may have wished to discuss, 8 either because they're there or because they're not 9 there, if I can put it that way? 10 PROFESSOR FORSYTHE: I think I would want to check that the initial assessment of the patient on admission was 11 12 correct and comprehensive, and I would also -- as 13 transplant surgeon, I would also be very interested 14 in the immunosuppression on the second page. I would 15 want to be involved in the decisions that were made 16 regarding immunosuppression. It would be done as 17 a joint thing between myself and an experienced nephrologist, but I would be keen to be involved in the 18 decisions that were made to set down that protocol. 19 Q. So given that the protocol covers those areas, however 20 21 briefly, that would be a reason for wanting to know 22 what's in the protocol? 23 PROFESSOR FORSYTHE: Yes.

Q. Thank you. I wonder if we could move now to thequestion of the phase which is sort of the prior to the

offer of the kidney, and taking it from Adam being placed on the transplant list. There has been some evidence from both Professor Savage and also Mr Keane about how that process worked, what meetings there were and between whom, and the extent to which the surgeons were or were not or could or could not have been involved in them.

8 You, I think, had in your reports referred to 9 multidisciplinary teams and the benefits of that, and 10 I believe that Dr Coulthard had similarly and also Dr Haynes. From your point of view, when do you think 11 12 the role of a surgeon in terms of putting a child on the 13 transplant list with a view to the child having 14 transplant surgery, when do you think the surgeon's role 15 really starts?

PROFESSOR FORSYTHE: When it is considered that the patient 16 17 may be suitable for the transplant list. So very early on in the process would be when we feel that a --18 19 particularly a complex young child like Adam --20 Q. Can I just pause there. Because that is an expression 21 that's very often used with Adam, and can I have your 22 view as to why you think he was a complex case? Let's 23 benchmark it. At the time when he was being put on the 24 transplant register?

25 PROFESSOR FORSYTHE: The main thing that strikes me as

a surgeon is the fact that this young lad had many
 previous operations and so that alone actually places
 him into a category for me which is more complex, and
 I would want to know as many details as possible before
 he goes on to that list.

Q. Sorry, just so that we understand, why is that? Why is
just the sheer number of his operations making it
a complex case?

9 PROFESSOR FORSYTHE: I was going on to say that the 10 assessment would be about the diagnosis of any surgical problems that there may be now, the problems that may 11 12 arise at the time of transplantation or immediately 13 following transplantation, looking for the most 14 successful outcome that there can be. Clearly, if 15 someone, anyone, has had multiple previous operations and particularly multiple previous abdominal operations, 16 17 then there is the capacity for each one of those 18 operations to affect, if you like, each of the different 19 categories that I have laid out to you. Hence, if someone has had previous surgery I would want to know 20 21 exactly what that surgery is, whether that affects my 22 assessment of him now and around the time of possible 23 transplantation.

Q. Would it make a difference how many operations, how far from the point in time when you're thinking of placing

the child on the transplant list those operations had 1 2 occurred? Would any of that be significant? PROFESSOR FORSYTHE: It's more the type of operation. 3 I 4 mean, somebody could have had multiple relatively minor operations, which it would be easily dismissible. But 5 б if they had had two major procedures, perhaps one on the 7 bladder, one on the area where you're going to plumb in 8 the new kidney, then those two operations alone would be 9 worrisome in terms of planning for the future.

I think you will have seen a schedule of Adam's surgical 10 Ο. procedures. I think you saw that when you were dealing 11 12 with the issue of the Broviac line. You will have seen 13 that initially his plumbing, as you put it, was the subject of operations. I think he had ended up with a T 14 15 shape, one ureter draining into another and then that ureter into the bladder, and that happened when he was 16 17 quite young. We can pull up the surgical procedure 18 schedule should anybody want to see that. We're 19 probably looking for it now.

20 MR FORTUNE: It's 300-060-107.

21 MS ANYADIKE-DANES: Thank you very much. There we are. 22 If we just increase that a little bit, if we can. The 23 sort of procedures that you were discussing that would 24 be of interest to you and which might add complexity or 25 at least you would want to know more details about,

1 can you identify that kind of procedure from this
2 schedule?

3 PROFESSOR FORSYTHE: I can try to. It is quite small print.
4 Q. Maybe if we take the first four and enlarge those?
5 PROFESSOR FORSYTHE: I think actually it may well be the
6 first four are the key ones.

7 Q. There we are.

PROFESSOR FORSYTHE: Yes, I think as you say, from the list 8 9 down, ureteric re-implantation, laparotomy, cystoscopy, 10 laparotomy, trans uretero-ureterostomy and laparotomy all of those are intra-abdominal procedures which 11 12 affect -- and I said 'plumb in the kidney' not --13 I didn't say about the plumbing of a patient. All those 14 would affect the area in which you would be planning to 15 operate. So all of those would be pertinent for you to know about in terms of just planning. It may not affect 16 17 what you do, but it's nice to know about it ahead of 18 time.

19 Q. And when you say it would affect you in terms of 20 planning, forgive me, how does it affect you in terms of 21 planning, what is the impact on your planning of 22 knowing, for example, that he had undergone in 1991 23 those four procedures?

24 PROFESSOR FORSYTHE: It's about the site of the surgical 25 incision, it's about whether or not there is likely to

be more scarring in the area and, therefore, making the operation more difficult. And that's not just about me knowing that it's going to be more difficult, it's also telling relatives what the anticipated difficulties might be.

б It's also about: is there something within the 7 set-up which is going to make infection more likely, 8 either during the transplant, when you're doing a second 9 operation? Or, alternatively, when the patient is 10 immunosuppressed, their immune system taken down slightly, is there a chance that there will be 11 12 infection, an increased chance there will be more 13 infection? And all of these are going through your mind 14 as you look at this list.

15 If that's relevant for a surgeon to know and consider as Ο. part of his planning, and I think your evidence a little 16 17 while ago was that you thought that a surgeon ought 18 really to be involved almost as soon as you've made the 19 decision that the child is going to go on to the transplant list, the situation that existed in Belfast 20 21 at that time was that there was, as the chairman has said, no dedicated surgeon who's going to carry that 22 23 out. So there will be no surgeon who's going to be 24 Adam's surgeon. There will be surgeons who have the expertise and skills to do it, but there's no guarantee 25

at any given time which one it will be. So if you're 1 2 in that situation and you also feel that Adam's surgical 3 history means it's quite important that this information is conveyed, how does that get done to make sure that 4 the surgeon on the day has the appropriate information 5 б to assist them in their planning? 7 PROFESSOR FORSYTHE: I think I remember that at the outset 8 you said "a surgeon" rather than "the surgeon", and 9 I think that is important, because I work in a team of surgeons and I may well see -- on a night for 10 transplantation, I may well see a patient who has seen 11 12 one of my colleagues for an assessment. I will trust 13 that colleague to have made an appropriate surgical 14 assessment and do all the things that I have just 15 alluded to. And on the night, I will then hope that all of the planning that I have mentioned has gone forward 16 17 and that will aid significantly in making sure that 18 there is a successful outcome. So if you work in a team 19 of surgeons, then as long as a surgeon who is experienced in transplantation has seen the patient, has 20 21 carried out the full assessment, then I am content. 22 THE CHAIRMAN: Okay. Let me just pick you up on that. 23 Going back to 1995. Back to 1994. 1994, Adam goes on 24 the list for transplant, okay? At that time, I understand your evidence is that it would have been 25

better if there had been some input from a surgeon at
 that point.

3 PROFESSOR FORSYTHE: A surgeon who was experienced in 4 transplantation, if I may.

5 THE CHAIRMAN: Okay, yes. And that means then that when as 6 it turns out it's Mr Keane who's called in and does the 7 operation starting on the 27th, what tangibly will he 8 have before him or on a file or anywhere, which gives 9 him the benefit of the input of the surgeon at the time 10 that Adam went on to the register?

PROFESSOR FORSYTHE: So, normally, the assessment procedure 11 12 would have been chronicled either by the surgeon 13 involved writing in the notes or, more likely, or maybe 14 in addition, a letter back to the referring 15 nephrologist, saying, "Thank you for asking me to see this patient, here are the problems, here are the things 16 17 I think we need to do about it now. I think they can go on the list". All of those things with the assessment 18 will have been carried out fully and will then be 19 available to Mr Keane or any transplanting surgeon on 20 21 the night.

22 THE CHAIRMAN: So instead of him coming in and trawling 23 through the notes or having to trawl through the notes 24 at comparatively short notice, he has the advantage that 25 somebody has already done this, has already examined

1 Adam and has given him this preparation for the

2 transplant he's about to do?

3 PROFESSOR FORSYTHE: As you say. I mean, it still would be 4 ideal that the surgeon would come in and still carry out 5 an assessment. But as you say, that assessment will be 6 short circuited and improved because of prior planning. 7 THE CHAIRMAN: Thank you.

MS ANYADIKE-DANES: When you say that an assessment will be 8 carried out, will that assessment involve considerations 9 10 as to how the surgery might actually be carried out? I presume there are a number of ways in which you can 11 12 carry out paediatric renal transplants. Will some 13 thought have already been given to that, bearing in mind 14 the child's specific anatomical circumstances, if I can 15 put it that way?

16 PROFESSOR FORSYTHE: Yes.

17 Q. Is that part of the judgment that you receive and the 18 benefit of that that you are using if you're the person 19 who comes in at the last moment?

20 PROFESSOR FORSYTHE: Yes.

Q. So effectively you don't have to think through all those options, you may be able to form a view of them, but somebody has already done some of that thinking based on the examination and the assessment?

25 PROFESSOR FORSYTHE: Correct. A simple example would be

that if somebody has had a previous transplant and the right lower side of the abdomen has already been used, then that's clearly going to be fully assessed and you can say the left side would be better to be used on this occasion. There are more complex examples of that same process, but you are correct that it does help short circuit the thought on the night.

Q. And when you said short circuit, I take it it doesn't
exclude it entirely. I presume it is still the
surgeon's responsibility to assess then to see if there
are any changes or differences since those assessments
or views were communicated or drawn up?
PROFESSOR FORSYTHE: As I answered the chairman, yes.

14 That's absolutely correct.

15 Now, that's what the surgeon is doing and why the Ο. surgeon's doing it. But a number of our experts, and 16 17 indeed for that matter, not that it happened in 1995 in 18 Belfast, but Professor Savage and Mr Keane have 19 acknowledged the benefit of multidisciplinary teams. But going back to 1995, when I think you, gentlemen, 20 21 were saying there were multidisciplinary teams in 1995, 22 how does that work in terms of how the other disciplines 23 help for the planning of what in due course one hopes 24 will be the offer of a kidney?

25 MR RIGG: Certainly in Nottingham at that time we used to

1 have a regular meeting where the nephrologists, the 2 transplant surgeons, specialist nurses, used to meet, and we used to discuss all patients who were ready to go 3 on to the list so that we could discuss those specific 4 points. We used to discuss every patient who was 5 б already on the list, so we could see whether things were 7 changing. We discussed everyone who had recently had 8 a transplant so we could see what had gone well, what 9 hadn't gone well, and this was repeated on a regular 10 basis. Q. You may not know, in fact I'm sure we have the 11 12 information, we can find out, but just in case you do 13 know, in 1995 roughly how many paediatric transplants 14 was Nottingham doing a year? 15 MR RIGG: At that stage we were doing around 8 to 10. 16 8 to 10 a year? Ο. 17 MR RIGG: At that stage, yes. I think it's also fair to say from the evidence we've seen, in 1992 there were only 18 19 102 paediatric transplants performed in the UK in ten 20 centres. When I last looked at the data, there were 21 about 150 paediatric transplants done a year now. So 22 it's not a high volume, although obviously a higher 23 volume in some centres than others. 24 MR FORTUNE: Sir, can we establish from Mr Rigg that in 25 Nottingham at that time all the members of the

multidisciplinary team were in fact based on one site? 1 2 Because what Mr Rigg needs to remember is that the urologists who would carry out the paediatric surgery 3 would come from the City Hospital on a different site. 4 MR RIGG: In 1995, we were on one site. Over the last four 5 б years we've been on two sites. So we are now doing it 7 by one team coming over to join the other team. MS ANYADIKE-DANES: The data that I just referred you to, 8 9 I think if we can pull up 300-021-033. Yes. There's 10 Nottingham, almost halfway. We can see, if you look down, it's grouped up to 14 and then 14 to 17. 11 There 12 we are.

13 If we look and see the pattern of what you were 14 doing, for the younger ones, which is the category that 15 Adam would have fallen into, you don't -- well, you had quite a high year in 1992 and a high year in 1994. But 16 17 apart from that, there were years actually when you 18 doesn't do any at all, then 3, 2, a 5, that's right of 19 thing. So would it be fair to categorise Nottingham as not a very large paediatric renal transplant centre? 20 21 MR RIGG: I think probably we were medium sized. Can I just 22 clarify for the columns? Because I think the first 23 column is the age under 14. So that's actually got the 24 larger number in. And the second column is the 14 to 17. 25

Q. Yes, that's exactly right, obviously somebody's got 1 2 their symbols round the wrong way. That's under 14 and the other one is 14 to 17. 3 4 MR RIGG: But obviously, in the under 14 group that's a fairly wide range, so that would include the 5 б two-year-olds to five-year-olds, which are obviously the 7 smaller children. But it would also include those 8 between five and 14, so it's quite a wide range within 9 that. MS ANYADIKE-DANES: It is. The point was, where we were is 10 you discussing these multidisciplinary teams, and what 11 12 you were discussing was a series of meetings even though 13 there may not actually be that many transplants being 14 carried out, was actually where I was taking you to on 15 that. But nonetheless, you had instituted this system, am I right in thinking -- was it in 1995 or did it exist 16 17 prior to 1995? MR RIGG: It existed when I arrived in Nottingham. 18 19 Q. Which was? 20 MR RIGG: In 1992. The paediatric nephrologist who had 21 started that single-handed had set these up, and by the 22 time I arrived there were two paediatric nephrologists and two transplant surgeons and we continued. 23 24 THE CHAIRMAN: Sorry, there were more children on the 25 transplant list than there are transplants?

1 MR RIGG: Yes.

2	THE CHAIRMAN: So this actually gives the number of
3	transplants, not the number of children on the list.
4	MR RIGG: That's right.
5	THE CHAIRMAN: But the multidisciplinary team meetings that
6	you are talking about are for the children who go onto
7	the list.
8	MR RIGG: We include those who go onto the list, those who
9	are coming up to going onto the list and those who have
10	been transplanted as well. So it will be larger numbers
11	than these that we discussed.
12	MS ANYADIKE-DANES: And that would be true for any centre
13	instituting that sort of system if they adhered to that?
14	MR RIGG: That's correct.
15	Q. Have you any idea of the sort of numbers that you'd be
16	dealing with of children who were on your list in 1995?
17	MR RIGG: Um It would be between 10 to 20 at any one
18	stage.
19	Q. Yes. Then what I was going to ask, if you could help us
20	with, is the disciplines that you have described,
21	participating in those meetings, we can see what the
22	surgeons are doing. In fact, it's of some value the
23	surgeons meeting together collaboratively and taking the
24	benefit of their pooled experience. But what exactly
25	was the plan that was if we stick with the meetings

that we're discussing, the children who were going to 1 2 have transplants, as opposed to those who had already 3 had them and you were monitoring them, for example, what exactly was the plan and the purpose of those meetings 4 for those children who were going to have transplants? 5 б MR RIGG: There were a number of factors. For some children 7 there may have been specific surgical or urological 8 factors, so it may have been they needed further 9 investigations on their bladder, for example, to make 10 sure they were suitable to take a transplant, or whether they would need to have a catheter put in afterwards. 11 12 There were factors to do with if a child was just about to go on to the list, what sort of match would we want 13 14 for that particular transplant. 15 You mean how urgent or acute might be the need for Ο. 16 a transplant? 17 MR RIGG: That's correct, and whether they -- whether 18 dialysis was going very straightforwardly, or whether 19 the options for dialysis were becoming fewer, in which

20 case we would need to look at ways in which we could 21 optimise that. It was also the opportunity to discuss 22 with the wider team whether living donation was an 23 option for those children because obviously for some it 24 was, but for others it was not. So there was a whole 25 range of medical and other factors that were considered,

1 each child was different and we would consider different 2 issues.

Q. Where is that information, the product of that discussion, where is that distilled so it is of use to those who, on the particular time when the kidney is offered, have the care and management of that child's surgery?

8 MR RIGG: We kept it on a database or a spreadsheet which 9 had the relevant information, and that was available to 10 our transplant coordinators, who took the call. It was 11 available to both the nephrologist and to the surgeons 12 who were on the rota.

Q. Can I ask you a question. You have said that one of the things you would be reviewing at a meeting like that is how well the dialysis was going. And you'd also said another thing that you would be forming a view of is how urgent this child's need for a transplant was.

18 What actually determines urgency of need, so far as 19 your experience was in 1995? This is a question 20 addressed to both of you in your practice in 1995. What 21 determined the urgency of a child's need for

22 a transplant?

23 MR RIGG: I think that was very much the view of the 24 nephrologist and the wider paediatric nephrology 25 multidisciplinary team. So it would also take a view of

the specialist nurses, who would know about how dialysis 1 2 was going. It would take the view of the psychologists of the social workers, of the play therapists, how 3 families were coping with their child who had renal 4 failure. So it wasn't just physical factors, it was 5 б also social and emotional factors as well. 7 Yes. Broadly speaking, although you might not be able Ο. 8 to answer it in that way, if a child was being 9 maintained very well on dialysis and was healthy, then what effect, if any, does that have on all other things 10 being equal, on the urgency of their need for 11 a transplant? 12 13 MR RIGG: I think that allows us to be a little more 14 selective in the organ that we accept for that 15 particular child. I think it's important to recognise 16 that the child has potentially many, many years ahead of 17 them, and many children end up with one, two, three, or 18 even four transplants as the years go by and, therefore, 19 it's important that each transplant lasts for as long as possible. So we would think about getting the best 20 21 match, for example, that we could because we know that 22 that goes with outcome.

Q. And in Adam's case, if multidisciplinary meetings were
happening in relation to his particular case, knowing
what you do of his medical notes and records and his

surgical history coming up to when he was placed on the transplant list -- you may not be able to answer this -what are the things that, in your view, would be being discussed or are likely to have been discussed in relation to him?

б MR RIGG: Again, I'm not sure I'm able to comment on the 7 specifics, but in general principles it was how well 8 he was managing on dialysis, whether he'd had any 9 episodes of peritonitis, whether the dialysis was 10 working well. It'd be those sorts of factors. THE CHAIRMAN: Can I just interpose because, to be fair to 11 12 Professor Savage, and the other witnesses from the 13 Royal, they've accepted that it would have been a better 14 system if they'd had the multidisciplinary team meetings 15 you're talking about if they'd had them in 1995. But he suspect you may make two points about it. One is that 16 17 he was getting a fledgling service up and running so he seems to have a bit less far down the road than either 18 19 of you were in Scotland, England or Nottingham.

20 The second point is that they were having 21 multidisciplinary team meetings of a different sort, 22 which involved nephrologists, renal nurses and

23 psychologists. Isn't that right?

24 MR FORTUNE: And sociologists.

25 THE CHAIRMAN: And sociologists. So I presume you'd agree

there would be a value to the then Northern Irish 1 2 multidisciplinary team meetings, even if they didn't 3 involve the surgeon, but your point would be they would have been more valuable had they included the surgeon; 4 would that be it? 5 б MR RIGG: I think transplant is but one aspect of caring for 7 a child with renal failure. So even in Nottingham there 8 were separate multidisciplinary teams that discussed all

10 multidisciplinary team meetings that were specifically 11 concentrated and focused on transplantation. So there 12 were other ones going on at the same time, which sounds 13 as though they were similar to those happening here in 14 Belfast.

These are

of the aspects of that child's care.

9

MS ANYADIKE-DANES: And I think, Mr Rigg, you said that you are actually now in the situation where your surgeons are coming from a different site. Is that what you said?

MR RIGG: That's what happens -- well, in fact, what happens now is that actually the nephrologists come to us rather than us go to them for the meetings.

Q. And what are the arrangements for how that works interms of your multidisciplinary meetings?

24 MR RIGG: We plan a specified meeting every three months

25 where we discuss those things. As well as including the

surgeons, the nephrologists, the specialist nurses, we 1 2 also include our colleagues from tissue typing, the histo-compatibility and genetic laboratories as well. 3 So we combine that meeting every three months formally, 4 but if there are other issues to discuss with specific 5 б patients in between time, then we will have a phone 7 conversation or an individual meeting. Q. But I take it that even though they might not be on the 8 9 same site they're all within the same trust? MR RIGG: That's correct. 10 I wonder if I could take you to the issue of live 11 Ο. 12 donation. I think you've said that that is one of the 13 sorts of things that would be being discussed in one or 14 other of those multidisciplinary meetings. 15 Now, I think it's Mr Keane who gave evidence -- this is 23 April transcript at page 138. I think we can pick 16 17 it up at 1. He said -- maybe go to the page before to see the context of that answer. 18 If we start at line 17, although it's 19 a conversation -- it's obviously a discussion that gets 20 21 raised slightly ahead of that. Line 17: 22 "The issue of the live donation, you could have it 23 as part of the discussion but I think with Mr Keane, 24 I wouldn't dream of a live donor procedure on Adam Strain." 25

1

And the question is:

2 "Why?

"Answer: You have to be a close relative, maybe his 3 mother. I would discuss this obviously with her, but 4 you the reasons would be if something happened to Adams' 5 б mother ... " 7 And then he's asked about the risks of that, if one goes over the page: 8 9 "Well, it's very low, but this is a consideration, that she might die. Living 10 donors have died or that she would have a major 11 complication of a major operation and be 12 13 seriously impaired in her ability to bring him up. Furthermore, the size of her kidney as 14 15 distinct from the size of the adolescent kidney ... " 16 17 Pausing there, the kidney that was offered for Adam was from a 16-year-old that he was to 18 19 receive, and then I say: "Can we just understand that, are you saying there 20 21 would have been a material difference in size between the 16 year-old donor kidney that Adam was ultimately 22 23 offered and his mother's kidney? 24 "Answer: Absolutely, yes, as an urologists conceptualise on this debate, yes, huge difference." 25

And then I asked if that was such a thing as to
 affect risk and he said:

3 "No, it wouldn't affect risk, it would affect the 4 type of procedure."

5 And then going on down to the issue of the live 6 donation:

7 "But the issue for Adam in a live donation is his weight and the potential size of his mother's kidney, 8 9 which you can assess, but if you're looking at it, you're talking about a small child taking a larger 10 kidney he has to work harder to drive it. There would 11 be a significant disparity in Adam's own capability to, 12 13 if you like, drive the kidney when coming from a 14 16-year-old as coming from an older adult."

And then he goes on that you would also havea placement issue:

17 "In my opinion, which would be that you would have 18 to consider an aortic placement of this particular 19 graft, which was, in my opinion, an aortic graft to me 20 in Belfast would -- no, you were going over to 21 Mr Koffman in Guy's if I thought that was the issue." 22 A number of matters raised there.

If one tries to tease some of them out so that we can have your views on them. Can we first start with whether, in Adam's circumstances, you would have been

discussing or it would have been discussed at 1 2 a multidisciplinary meeting the question of live donation if the mother had asked about it? 3 4 PROFESSOR FORSYTHE: I think it would. We have discussed this and I think even in 1995 when live donation was 5 б perhaps not considered so strongly, as it is today, but 7 even in 1995 we would have considered the possibility of 8 live donation. We would have discussed that. That is 9 another advantage, as we've hinted, of the assessment 10 process, as the possibility of Adam going on to the transplant list gives the opportunity to open out 11 12 discussions about living donation. It is very hard, 13 obviously, to raise that without producing some element 14 of coercion on the potential donor but, of course, we 15 want to make people aware of that possibility and discuss with them very openly the positives and 16 17 negatives that are associated with a live donor procedure for a child like Adam. 18 Q. Can I ask, in 1995, how much discussion would there have 19 20 been in 1995 of a live donation and what were its 21 relative benefits? 22 PROFESSOR FORSYTHE: In 1995, I think the possibility of 23 live donation would at least have been raised. If any 24 family member showed an interest in live donation,

we would then want to give more information. I take

25

1 absolutely what Mr Keane says that there are risks of 2 complications, and there is even, as he has noted, a risk of death following a live donation. But what 3 we would try to do in that circumstance is simply 4 provide as much information as possible and in 5 a supportive way help to make a decision as to whether 6 7 this is the opportunity that Adam and his potential 8 donor want to take on further. 9 0. And the benefits of it over and above, as in 1995, over 10 and above a cadaveric transplant? PROFESSOR FORSYTHE: Live donation is probably the best, the 11 12 most successful form of transplantation, of kidney 13 transplantation. That's for a number of different reasons, probably because of the -- in general the 14 15 better match of the kidney, even in 1995, and also the fact that, if you like, you can check the quality of the 16 17 kidney that is about to be transplanted. So it is a very successful form of donation for a child. 18 19 In addition, when there is any complexity to any patient who is to receive a transplant, performing 20

a live donor transplant is sometimes preferable because, of course, you can say it is going to happen almost in an elective way during daylight hours and the recipient can be brought into the best possible shape for the transplant to go ahead, and so a live donor transplant

1 is perhaps a good option to at least look at.

2 I'm not saying for one moment that that is the thing 3 that would have gone through, but it is at least a reasonable thing to have looked at. 4 THE CHAIRMAN: In fact Mr Keane said two things, there were 5 б live donations in Northern Ireland by 1995 but not 7 paediatric and, secondly, if this had been the route 8 that Adam's mother went down, it would have been in 9 London, not in Belfast. It would not have been carried 10 out here. MR FORTUNE: Sir, bearing in mind the topic presently under 11 12 discussion involves the multidisciplinary team, can 13 I invite my learned friend to put in front of Mr Rigg 14 and Mr Forsythe what Professor Savage had to say on this 15 topic because it's particularly apposite, so far as Adam is concerned. It is 17 April, page 69. 16 17 MS ANYADIKE-DANES: It starts at line 9, I believe. 18 MR FORTUNE: They might like to look at the bottom of 19 page 68 and read that large paragraph on page 69 and even go down to page 70. 20 21 THE CHAIRMAN: Can you give us 68 and 69 together, please, 22 to start? Thank you. 23 MS ANYADIKE-DANES: I think it starts right down at line 25: 24 "So I am aware that Debra Strain offered to become a live donor for Adam, and of course Adam was her entire 25

life and I accept that. As her nephrologist and his 1 2 nephrologist, I don't recollect exactly what I said to her, but my feeling would have been that Adam was 3 totally dependent Debbie Strain. He was very close to 4 her. He was very dependent on her. She looked after 5 б all his dialysis, all his tube feeds, all his medicines, 7 she lived and breathed for that little boy. He was a lovely little boy. So my feeling probably was that to 8 9 do one of our first live donor transplants in that situation, where there's a risk to the mother and a risk 10 of failure -- because he's so small, putting an adult 11 12 kidney into a small child -- and also the idea that she 13 would be little in a different hospital and not be there 14 for him during the transplant and because she was 15 a single parent, although I accept of course that his grandparents were enormously involved in his care as 16 17 well, I thought on balance that that was something we should not pursue and I believe I advised her: let's put 18 19 him on call and see if we can get a cadaver transplant and then you will be there to look after and support 20 21 Adam through that transplant. And I think that was probably the discussion that we had." 22

23 Then he was asked what the actual risks to her were, 24 and he asked: in percentage terms? If we go over the 25 page to 70:

"I don't know. They'd be fairly slight, but she 1 2 could be unwell for six months afterwards." And then there is an acknowledgment at line 8 that 3 it probably would have been better in terms of the 4 actual outcome, improved chances for Adam: 5 "But you'd still be putting an adult kidney into 6 7 a small child. If you remember, the kidney was selected from a 16-year-old, which is not quite an adult." 8 9 If we pause there, because those are two points that I wanted to raise with you out of what Mr Keane had 10 The chairman had quite properly taken you to what 11 said. Mr Savage was saying, but the two points that I wanted 12 to draw out of what Mr Keane said -- can we go back to 13 where we had his evidence, please, which I think was 14 15 138? Thank you very much. 24 April. THE CHAIRMAN: The 23rd. 23 April. 16 17 MS ANYADIKE-DANES: I beg your pardon. 23 April, sorry. 18 The two points I wanted to draw out was this first issue as to how significant it was for the chances of 19 success of a live donation that his mother's kidney 20 21 would be an adult kidney as opposed to what he actually was offered was a 16-year-old kidney. Of course, he 22 23 didn't ever have that option directly staring him in the 24 face, you could have a 16-year-old one or you could have an adult one, but I think what was being signalled was 25

that there was a material difference to him in having an 1 2 adult kidney as opposed to having a 16-year-old kidney. 3 Can I have your views on that? 4 PROFESSOR FORSYTHE: Sorry, Mr Chairman, it was just the 5 testimony of Professor Savage. It seems to me that was б just read out to me -- that seems to me that the 7 professor's having to have thought very carefully about 8 the whole issue of live donation and had tried to think 9 through the whole thing and had tried to make a decision, obviously with a great deal of thought that 10 was the right thing. So I'm not sure how much that had 11 12 been shared with Adam's mother. But that seems to be an entirely appropriate thought process that he was going 13 14 through. I just wanted to say that. 15 THE CHAIRMAN: I think if there was to be any point made on

16 that, it would be that, as I understand it, and I am 17 subject to correction, that was his thought process, but 18 it hadn't been shared with Adam's mother. And I get the 19 feel from you that your point is that you would not 20 necessarily be critical of that thought process, but 21 that is something which should be discussed with her? 22 PROFESSOR FORSYTHE: Spot on.

23 MR FORTUNE: To put Mr Forsythe's mind at rest. Because on 24 18 April, Day 2 of Professor Savage's evidence at 25 page 36, starting at line 8, and this will help

1 Mr Forsythe:

2	"Debbie Strain and I have a very close working
3	relationship. I was very close to her son, Adam. So
4	I think when you're talking to parents in these
5	situations, some of them will demand or expect to know
6	every minute detail."
7	Moving on to line 19:
8	"I don't know the exact situation with Debbie then,
9	but I do know this I trusted her care of Adam and she
10	trusted mine. Therefore, the information that I gave
11	her would have been in that mutuality trusting
12	situation."
13	THE CHAIRMAN: Thank you.
14	MS ANYADIKE-DANES: Just for completeness, can we have
15	Debbie Strain's own evidence? It's 001/2 at page 5.
16	MR FORTUNE: I accept what's about to be given. I'm merely
17	helping Mr Forsythe as far as his state of knowledge is
18	concerned.
19	MS ANYADIKE-DANES: Absolutely. The only reason for pulling
20	this up is that the chairman was expressing his
21	recollection of the evidence had as to whether indeed
22	that thought process was shared with the mother. So far
23	as the mother's evidence is, it wasn't.
24	She had raised the issue of a live donor and there
25	we are:

1 "Did anyone ever discuss with you the possibility of 2 using a living donor?

3 "Answer: I asked if I could donate, but as a single
4 parent this was not allowed, apart from that there was
5 no other discussion on a living donor."

6 So you have his thought process and I think the 7 point that the chairman was putting is the issue as to 8 the extent to which that thought process, in whatever 9 style he chose to do it, bearing in mind his knowledge 10 of the mother, to what extent that should have been 11 shared with the mother. I think that was the point that 12 the chairman was putting to you.

13 And before I move on, just so we don't leave that 14 hanging, do you have an observation or a comment on 15 that? Obviously he knew the mother, so he has that 16 knowledge and you don't have it. But do you have an 17 observation?

18 PROFESSOR FORSYTHE: I agreed with what the chairman said, 19 that I felt that Professor Savage has obviously thought that through very carefully and I would have hoped that 20 21 would have been discussed fully with Adam's mother. Thank you. Then can we go to the more medical issues 22 Q. that I was asking you about, which is this issue of the 23 24 significance or not of Adam's mother's kidney, if that was to be the kidney to be transplanted into him, being 25

an adult kidney. How relevant is that?

1

2 PROFESSOR FORSYTHE: I'm not sure of the relevance of that. I think before we looked into some of the detail that 3 has been provided, I think we felt that the 16-year-old 4 kidney that was ultimately transplanted into Adam was 5 near adult size. That's how I would have catchphrased 6 7 it, if you like. And I still am of that feeling, even with references that have been provided regarding the 8 9 size of kidneys.

If we pause there, maybe I will ask the point in this 10 Ο. way. To you as surgeons, as the transplant surgeon, is 11 there -- and you've explained how you would look at all 12 13 these issues and formulate your plan and so forth. Is 14 there much difference to you as surgeons that you're 15 told that you're going to be dealing with a donor kidney from a 16-year-old as opposed to a donor kidney from the 16 17 child's mother?

18 PROFESSOR FORSYTHE: There isn't a great deal of difference 19 in that, no.

20 Q. Does it add to the risks in any way?

21 PROFESSOR FORSYTHE: It adds to the risk only in that trying 22 to think through what Mr Keane was talking about in the 23 sections that you read out to me before in that when the 24 kidney is moved from a live donor, the vessels have to 25 be removed obviously in a safe way for the donor. So

the vessels are relatively short. So that makes the technical aspect of the surgery even more difficult. So there is a part of the process which becomes more difficult.

5 However, the approach to the recipient and how that kidney is, if I may use the term again, plumbed in, is 6 7 largely the same. So for me, I do not feel that the 8 actual recipient procedure is changed remarkably. 9 Thank you. Can I go back to that page and pull up just Ο. 10 one point, because I think you've mentioned it, but just to get your view on it. I think it's 23 April, 11 page 138. Maybe if we go over the page. It's where he 12 13 talks about the aorta. There we are. 14 It starts at line 7:

15 "There would be a placement issue in my opinion, 16 which would be that you would have to consider an aortic 17 placement of this particular graft and that an aortic 18 graft to me in Belfast ..."

19 And I presume he means then in 1995:

20 "... no, you were going over to Mr Koffman in Guy's21 if I thought that was the issue."

First, if you can explain why it is that putting in an adult kidney requires an aortic graft, and what's the significance of that?

25 MR RIGG: I think it's probably more to do with Adam's size
rather than the size of the kidney. Adam was a small 1 2 child, he was around 20 kilograms, between four and five years of age. And in children of that size and 3 age, we would go for a larger blood vessel because the 4 relative flow in a child is lower than it is in an 5 б adult. Therefore, if you're going to put in a larger 7 kidney, then you want to ensure that the flow into that 8 kidney is as good as you can make it and, therefore, it 9 makes far more sense to use one of the larger vessels than one of the smaller vessels. 10

Q. If I have understood you correctly from what Mr Forsythe was saying and you have just said now, does that mean that if the 16-year-old donor kidney going in, an adult kidney going in would actually not have made any difference to the fact that you would have wanted to plumb him in, I think Mr Forsythe's expression, to those larger vessels in any event?

18 MR RIGG: That's correct.

Q. Can you then express a view on the fact that Mr Keane is saying if you were going to go an aortic graft, so plumb it into that larger vessel, then that is not something that he would be comfortable doing in Belfast and that is something that Adam would be taken to -- well, elsewhere to a centre which perhaps has more experience, expertise or support. You mentioned specifically

Mr Koffman in Guy's. What is it about doing an aortic
graft that might lead to that conclusion?
MR RIGG: I think there were two aspects. One is to make
sure you're able to expose the aorta and the inferior
vena cava, which are the major blood vessels in the
abdomen. That does mean often a larger incision to get
to that place.

8 It's also a part of the -- I suppose those vessels 9 are not vessels that many surgeons deal with in their 10 normal daily practice. Vascular surgeons may do, but for the majority of other surgeon, urologists, general 11 surgeons, that's not an area that many would feel 12 13 comfortable with, and because children of this age, there are not that many, therefore many surgeons do not 14 15 gain that experience.

16 Perhaps I can just use an illustration from my own 17 unit, if I may. There are five of us. Four of us are 18 comfortable in approaching the aorta and doing small 19 children. One of my other colleagues is more of a full-time urologist, but he helps us out on the rota, 20 21 but he has said that he does not do children because he does not feel comfortable in dealing with those larger 22 23 vessels.

Q. And, as far as you're concerned, that is because, as Iunderstand you, in your view, an adolescent or an adult

1 kidney, to give it its best chance of success, needs to 2 be plumbed up to those larger vessels, given Adam's 3 size, so that it has the best flow of blood; is that 4 what you're saying?

5 MR RIGG: It is, yes.

б PROFESSOR FORSYTHE: Just to confirm, it is one of the 7 larger vessels, so it is either -- as I think has been 8 presented in other evidence, either the common iliac 9 vessel or the aorta, which you'll be able to, if you 10 like, use either one of those if necessary. So if you are attempting to put a more large kidney into a small 11 child, then we both feel that it would be suitable that 12 you should be prepared to use any of those vessels and 13 14 particularly the larger vessels.

15 Q. Now, just so that we're clear about it, Mr Rigg, the colleague of yours who wouldn't be prepared to do an 16 17 aortic graft, is that shorthand for saying he wouldn't be prepared to in a small child using any of those 18 19 larger vessels, not just confining himself to the aorta? 20 MR RIGG: He wouldn't be prepared to transplant a small 21 child. He's happy with teenagers where he's able to use 22 the conventional blood vessels, but he said he does not 23 want to do small children.

Q. So the issue is the plumbing into the larger vessels andthe approach required for that, as opposed to whether

1 it's plumbing into the aorta or one of the larger 2 iliacs? That's the issue, it's the fact that you're 3 going for these larger vessels?

4 MR RIGG: That's correct.

So if Adam -- in your view then, if that's what's 5 Ο. б required, that would mean that unless Adam was being 7 offered a kidney that didn't require that sort of blood 8 supply because it was smaller and more in keeping with 9 his own size, that was always going to pose a problem? MR RIGG: I think it's probably always going to pose 10 a problem whatever the size of kidney. I mean, there 11 12 was certainly evidence that using kidneys from similar 13 aged children actually resulted in a higher risk of those vessels thrombosing or blocking off, and I think 14 15 that's what helped people to understand that actually it 16 was the flow into these kidneys that was more of 17 an issue and why it was more important to use a larger 18 blood vessel to plumb them on to rather than a smaller 19 one.

Q. I see. And so the other way around, when you're dealing with a small kidney, is it because you've got tiny vessels and it's the difficulty of connecting those up, and when you're dealing with a large kidney it's because the small vessels of the recipient can't provide a sufficiently inadequate blood supply to the larger

kidney?
MR RIGG: Th

2	MR RIGG: There's various laws in physics, but one tells us
3	about the flow in a blood vessel, and it's to do with
4	the radius of the blood vessel. But actually, the
5	smaller the blood vessel is the lower the flow. And
6	that's not proportional, it's much more than that. So
7	if you halve the diameter of a blood vessel, then the
8	flow probably goes down by about eight times.
9	Q. Just that we are clear, what are the implications of
10	that for the success of the surgery or the transplant,
11	I should say?
12	MR RIGG: The implications are to use
13	Q. No, no, the implications of not having used the larger
14	vessels for the success of the transplant?
15	MR RIGG: If you use the smaller vessels, then the
16	implication is that that kidney or the vessels of
17	that kidney are far more likely to thrombose and block
18	off in the period immediately after the transplant.
19	Q. And if they block off?
20	MR RIGG: The kidney is lost.
21	Q. Thank you. Mr Chairman, I'm just
22	MR FORTUNE: Sir, can I suggest that actually we adjourn for
23	the afternoon? It's getting very warm in here and it's
24	not the first afternoon where it's got very warm. I'm
25	not referring to my learned friend's questioning!

THE CHAIRMAN: I'm fine with that, Mr Fortune. These two 1 2 witnesses will continue tomorrow. In very crude terms, there's about three and a bit pages of questions. 3 4 I think we've reached the bottom of page 1. We have to finish them tomorrow and if we stop now, what time can 5 б we start out tomorrow to make sure we do finish? 7 MR FORTUNE: Sir, at the risk of upsetting my learned friend Mr Millar, 9.45? 8 9 THE CHAIRMAN: Is that okay? If we get a good morning done, we'll be on schedule comfortably for tomorrow afternoon. 10 Thank you very much. 11 12 MR UBEROI: Sir, have you formed a view yet as to the 13 potential witnesses for next week? THE CHAIRMAN: Yes. If you wait for five minutes after 14 15 I finish --MR MILLAR: Sir, have you formed a view as to when you're 16 17 going to start not sitting on the Fridays? THE CHAIRMAN: I think for the next two weeks we'll sit on 18 Fridays and we'll do everything we can not to sit on 19 20 Fridays when we resume in June. (4.25 pm) 21 (The hearing adjourned until 9.45 am the following day) 22 23 24 25

1	I N D E X
2	PROFESSOR RUPERT RISDON (called)
3	Questions from MS ANYADIKE-DANES
4	QUESCIONS FION NO INCLUSING DIALO
5	DR SIMON ROBERT HAINES (CONCLINED)
б	Questions from MS ANYADIKE-DANES41 (continued)
7	Questions from MR HUNTER130
8	Questions from THE CHAIRMAN131
9	PROFESSOR JOHN FORSYTHE and MR KEITH136 RIGG (called)
10	Ouestions from MS ANYADIKE-DANES
11	2 402 0 - 2 0 m 1 D 1 - 1 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	